<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of thoracic aortic aneurysm in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of thoracic aortic aneurysm in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of thoracic aortic aneurysm in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher R Burke, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James Hoekstra, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Heidi M Connolly, MD, FACC, FASE</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gabriel S Aldea, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Edward Verrier, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Thoracic aortic aneurysm (TAA) can be due to one of several etiologies. The natural history of TAA is one of progressive expansion, the rate of which depends upon the location of the aneurysm and its underlying cause. Although most TAAs produce no symptoms, patients who become symptomatic or have complications related to the aneurysm (eg, acute aortic regurgitation, dissection, aortic rupture) should undergo repair [<a href="#rid1">1-5</a>]. Conservative management of asymptomatic TAA aims to lessen stress on the aorta and limit further aortic expansion. Asymptomatic patients who do not meet criteria for repair also require ongoing aneurysm surveillance. Any patient with additional clinical risk factors (eg, Marfanoid habitus, positive family history) should be evaluated for possible underlying genetic conditions known to be associated with thoracic aortic aneurysm and dissection (TAAD). Where expertise in the management of thoracic aortic disease is not available, the patient should be transferred to a high-volume cardiovascular center with a multidisciplinary aortic team to provide the best possible outcome [<a href="#rid6">6</a>].</p><p>The management of thoracic aortic aneurysm is reviewed here. The etiology, natural history, clinical features, and diagnosis of TAA, as well as specific techniques for repair of the thoracic aorta, are discussed separately. (See  <a class="medical medical_review" href="/d/html/88937.html" rel="external">"Epidemiology, risk factors, pathogenesis, and natural history of thoracic aortic aneurysm and dissection"</a> and  <a class="medical medical_review" href="/d/html/8192.html" rel="external">"Clinical manifestations and diagnosis of thoracic aortic aneurysm"</a> and  <a class="medical medical_review" href="/d/html/8191.html" rel="external">"Endovascular repair of the thoracic aorta"</a> and  <a class="medical medical_review" href="/d/html/88951.html" rel="external">"Overview of open surgical repair of the thoracic aorta"</a>.)</p><p class="headingAnchor" id="H3875911"><span class="h1">INDICATIONS FOR REPAIR</span><span class="headingEndMark"> — </span>We agree with major cardiovascular society guidelines from the American College of Cardiology, American Heart Association, and Society of Vascular Surgery that recommend repair for <strong>all</strong> symptomatic thoracic aortic aneurysm (TAA; ruptured, associated with dissection, causing pain) [<a href="#rid1">1-5,7,8</a>]. In general, repair of asymptomatic TAA is not recommended until the risk of rupture or other complications exceeds the risks associated with repair. Asymptomatic TAAs are selected for repair depending upon diameter, location, expansion rate, family history of rupture/dissection, and the presence of associated coronary heart disease or valve pathology requiring surgical intervention, with special considerations depending on the presence of underlying contributing etiologies (eg, connective tissue disorders, bicuspid aortic valve, familial thoracic aortic aneurysm/dissection). For patients who meet the criteria for repair, survival is improved for open surgery compared with medical therapy alone [<a href="#rid4">4,5</a>]. This should also be the case for endovascular repair given that endovascular repair compares favorably with open surgery. Asymptomatic patients with TAA who do not meet criteria for repair are managed medically with routine surveillance. (See <a class="local">'Management of asymptomatic TAA'</a> below.)</p><p class="headingAnchor" id="H4272180008"><span class="h2">Summary of indications</span><span class="headingEndMark"> — </span>Recommendations for repair for TAA in the ascending  (<a class="graphic graphic_table graphicRef115163" href="/d/graphic/115163.html" rel="external">table 1</a>) and descending thoracic aorta are summarized and discussed in detail below. (See <a class="local">'Symptomatic (nonruptured) and ruptured TAA'</a> below and <a class="local">'Asymptomatic TAA'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>Symptomatic (nonruptured) or ruptured TAA. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Asymptomatic ascending TAA [<a href="#rid7">7</a>]: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>End-diastolic aortic diameter &gt;5.5 cm [<a href="#rid5">5,8</a>], <strong>or</strong> aortic size index (aortic diameter [cm] divided by body surface area [m<sup>2</sup>]) ≥2.75 cm/m<sup>2</sup> [<a href="#rid9">9</a>] <strong>or</strong> aortic area over height ratio (ie, maximal aortic cross-sectional area [cm<sup>2</sup>] divided by height [m]) &gt;10 cm<sup>2</sup>/m [<a href="#rid4">4,5</a>]. A body surface area calculator can be found in the link (<a class="calc calc_professional" href="/d/html/13410.html" rel="external">calculator 1</a>). (See <a class="local">'Degenerative TAA'</a> below and <a class="local">'Accounting for body size'</a> below.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Surgery can be considered for patients with &gt;5 cm aortic root/ascending aortic aneurysms when bicuspid aortic valve is present or for those with a trileaflet aortic valve, if surgery is performed at a comprehensive multidisciplinary aortic team. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Surgery is indicated for patients with an aneurysm of the aortic root or ascending aorta of &lt;5.5 cm, but an expansion rate of ≥0.3 cm per year in two consecutive years, or ≥0.5 cm in one year.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with a height &gt;1 standard deviation above or below the mean who have an asymptomatic aneurysm of the aortic root or ascending aorta and a maximal cross-sectional aortic area/height ratio of &gt;10 cm<sup>2</sup>/m, surgery is reasonable when performed by experienced surgeons in a multidisciplinary aortic team.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with genetically mediated thoracic aortic aneurysm and dissection (TAAD), including syndromic conditions such as Marfan, Loeys-Dietz, vascular Ehlers-Danlos, and Turner syndromes, as well as nonsyndromic conditions like familial TAAD or bicuspid aortic valve, a lower diameter or aortic index is suggested as an indicator for repair  (<a class="graphic graphic_figure graphicRef115223" href="/d/graphic/115223.html" rel="external">figure 1</a>). The specific threshold diameter depends on the condition. (See <a class="local">'Genetically mediated thoracic aortic aneurysm and dissection'</a> below and <a class="local">'Accounting for body size'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients undergoing aortic valve surgery or coronary artery bypass grafting: End-diastolic aortic diameter &gt;4.5 cm in diameter. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Asymptomatic descending TAA: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most average-sized adults: Diameter of &gt;5.5 cm [<a href="#rid5">5,8</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with high surgical risk for repair (eg, Society of Thoracic Surgeons Predicted Risk of Mortality [PROM] score &gt;8 percent, frailty score index &gt;2, two compromised organ systems [<a href="#rid10">10</a>]): Diameter ≥6 to 7 cm.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with genetically mediated conditions (syndromic or nonsyndromic) or other factors that increase the risk of rupture (eg, aneurysm expansion &gt;0.5 cm per year, saccular aneurysm, infectious aneurysm, female sex), a smaller diameter is suggested as an indicator for repair [<a href="#rid7">7</a>]. The specific threshold diameter depends on the condition. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For smaller patients, including many females, a diameter greater than twice the diameter of the nonaneurysmal aorta (normal segment) or the aortic size index can be used. (See <a class="local">'Accounting for body size'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Asymptomatic TAA with rapid expansion ≥5 mm per year for aneurysms &lt;5 cm in diameter [<a href="#rid5">5,11</a>]. </p><p></p><p class="headingAnchor" id="H3876529"><span class="h2">Symptomatic (nonruptured) and ruptured TAA</span><span class="headingEndMark"> — </span>Although most TAAs are asymptomatic, TAA can produce a variety of symptoms and complications, which can be life-threatening. Chest pain associated with TAA could represent rapid aneurysm expansion, dissection, or rupture. Chest pain associated with evidence of acute dissection in a true thoracic or thoracoabdominal aortic aneurysm can be the first and only sign of a TAA [<a href="#rid12">12</a>]. Others may rarely present with dysphagia or dyspnea, usually related to compression of adjacent organs [<a href="#rid4">4,5</a>]. Patients whose symptoms can be attributed to the aneurysm should undergo repair [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/8192.html" rel="external">"Clinical manifestations and diagnosis of thoracic aortic aneurysm", section on 'Symptomatic TAA'</a> and <a class="local">'Thoracic aneurysm repair'</a> below.)</p><p>It has been suggested that patients with untreated large ascending or descending thoracic aneurysms are more likely to die of complications associated with their aneurysms than from any other cause [<a href="#rid13">13</a>]. In several series of patients, aneurysm rupture occurred in 32 to 68 percent of medically treated patients, and rupture accounted for 32 to 47 percent of deaths [<a href="#rid14">14-18</a>]. One-, three-, and five-year survival rates for unrepaired thoracic aneurysms are approximately 65, 35, and 20 percent, respectively. After rupture (or other complications), cardiovascular disease is the second most common cause of death among candidates who do not undergo repair. The overall mortality associated with ruptured TAA is high. Only approximately one half of patients with ruptured TAA live long enough to be transferred to the emergency department for treatment [<a href="#rid19">19</a>]. Without repair, ruptured TAA is nearly uniformly fatal. Unfortunately, regardless of the method of repair, a large portion of patients with ruptured TAA still do not survive [<a href="#rid4">4,20</a>]. </p><p class="headingAnchor" id="H3876712"><span class="h2">Asymptomatic TAA</span><span class="headingEndMark"> — </span>Elective repair of asymptomatic TAA may reduce the morbidity and mortality associated with TAA complications, but elective repair of asymptomatic TAA is not recommended until the risk of rupture or other complications exceeds the risks associated with repair. Favorable outcomes for open or endovascular repair reinforce the need to repair TAA before it reaches the thresholds described below (diameter, expansion rate), above which the risk of rupture increases sharply [<a href="#rid21">21,22</a>]. </p><p>The most important determinant of TAA rupture is the diameter of the aneurysm [<a href="#rid13">13,23-26</a>]. Other factors, such as a rapidly expanding aortic diameter, concomitant bicuspid aortic valve, or connective tissue disease, also increase the risk for rupture [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/d/html/88937.html" rel="external">"Epidemiology, risk factors, pathogenesis, and natural history of thoracic aortic aneurysm and dissection"</a>.)</p><p class="headingAnchor" id="H2231878176"><span class="h3">Diameter criteria</span><span class="headingEndMark"> — </span>The most important determinant of TAA rupture or other complications (eg, dissection) is the diameter of the aneurysm [<a href="#rid17">17,23-25,27</a>]. The diameter threshold to recommend elective repair varies by the location and etiology of the aneurysm, among other factors [<a href="#rid17">17</a>]. One group has shown that the clinical threshold for rupture mirrors the innate physical limits of the aortic wall. As the aorta approaches 6 cm, its distensibility rapidly falls [<a href="#rid28">28</a>]. At this diameter, the aorta loses its natural elasticity and effectively becomes a rigid tube. At a blood pressure of 200 mmHg, easily achieved through strenuous exercise or emotional distress, the stress generated in the wall of a 6 cm aorta can attain or exceed the maximum tensile strength of aortic tissue [<a href="#rid28">28</a>]. </p><p class="headingAnchor" id="H2579624299"><span class="h4">Degenerative TAA</span><span class="headingEndMark"> — </span>For patients with degenerative TAA (ie, <strong>not</strong> associated with genetically mediated conditions), we suggest elective repair of ascending TAA for end-diastolic aortic diameter &gt;5.5 cm, and elective repair of descending TAA with a diameter &gt;5.5 cm for patients with a low risk for perioperative complications. For higher-risk patients, a descending aortic diameter &gt;6 cm should be repaired [<a href="#rid5">5,8,17,23-25,27</a>]. What constitutes high risk is not well defined. The use of the Society of Thoracic Surgeons Predicted Risk of Mortality (PROM) score &gt;8, frailty score &gt;2, and more than one major organ system impairment has been used in an effort to stratify risk for aortic surgery in those with bicuspid aortic valves [<a href="#rid10">10</a>]. </p><p>Based on observational studies, the risk of complications of TAA (rupture, dissection) increases with larger aortic diameter, in particular, once the ascending aorta expands beyond 6 cm, or the descending aorta expands beyond 7 cm [<a href="#rid27">27</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>An early study of 133 patients with ascending TAA, descending TAA, or both found that the overall five-year risk of rupture was 0 percent for those less than 4.0 cm compared with 16 and 31 percent for TAA 4.0 to 5.9 and ≥6.0 cm, respectively [<a href="#rid23">23</a>]. TAA diameter &gt;6.0 cm was associated with a 15.6 percent per year combined endpoint of rupture, dissection, or death.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another series of 370 patients, the median diameter at the time of rupture or dissection was 5.9 cm for ascending TAA and 7.2 cm for descending TAA; a diameter greater than 6 cm increased the risk of rupture or dissection by 25 percent for an ascending TAA, while a diameter greater than 7 cm increased the risk by 37 percent for descending TAA [<a href="#rid25">25</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a later prospective study that included 304 patients with mostly ascending TAA (72 percent), overall rates of dissection or rupture were 2, 3, and 7 percent per year for TAA less than 5.0 cm, 5.0 to 5.9 cm, and ≥6.0 cm, respectively [<a href="#rid17">17</a>]. The combined endpoint of rupture, dissection, or death overall occurred at a rate of 16 percent per year among patients with TAA ≥6.0 cm. The overall five-year survival rate in patients with TAA &gt;6.0 cm was 56 percent. In patients who did not undergo surgery (diameter not specified), 54 percent were alive at five years. By comparison, elective surgery restored survival to a rate similar to a matched control population. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another review of 216 patients assessed, 41 percent of patients were considered high risk for any intervention [<a href="#rid18">18</a>]. Median TAA diameter was 6 cm. Over a median follow-up of 12 months, 49 of 81 patients died, of which 23 deaths were due to rupture; the others were not aneurysm related. </p><p></p><p>Even though the risk of dissection or rupture increases with aortic diameter, most patients who present with dissection have smaller-diameter aneurysms. In a review of 591 patients with type A dissection enrolled in the International Registry of Acute Aortic Dissection (IRAD), the mean diameter was 5.3 cm [<a href="#rid12">12</a>]. Nearly 60 percent of patients had an ascending aortic diameter &lt;5.5 cm, and 40 percent had an aortic diameter &lt;5.0 cm.</p><p>Clinicians should understand the limitations of basing treatment decisions solely on diameter criteria. Data have called into question the traditional cutoff of 5.5 cm for degenerative TAA, and some have called for potentially lowering this threshold [<a href="#rid29">29</a>]. Reasons for this include prospective natural history studies showing a "hinge-point" for TAA complications at 5.25 cm (in addition to previously described 5.75 cm), recognition that the aorta "increases" in diameter by 7 mm at the moment of dissection, along with increased safety of contemporary elective TAA repair. Further work will be needed in this area to better predict those patients who would benefit from prophylactic TAA repair at smaller diameters.</p><p class="headingAnchor" id="H2668200540"><span class="h4">Inflammatory TAA</span><span class="headingEndMark"> — </span>Inflammatory diseases such as Takayasu arteritis, giant cell arteritis, Behçet disease, and ankylosing spondylitis are commonly associated with TAAD [<a href="#rid4">4,5</a>]. TAA formation may occur at multiple sites over a period of follow-up. Initial medical therapy for active Takayasu arteritis and active giant cell arteritis reduces the active inflammatory state. Elective surgical repair of TAA for patients with Takayasu arteritis and giant cell arteritis should be delayed until the acute inflammatory state is treated and quiescent. The diameter criteria for inflammatory TAA repair are the same as those for noninflammatory, degenerative TAA [<a href="#rid4">4,5</a>]. (See  <a class="medical medical_review" href="/d/html/88937.html" rel="external">"Epidemiology, risk factors, pathogenesis, and natural history of thoracic aortic aneurysm and dissection", section on 'Inflammatory disorders'</a> and  <a class="medical medical_review" href="/d/html/8224.html" rel="external">"Overview of the management of vasculitis in adults"</a>.)</p><p class="headingAnchor" id="H3877097"><span class="h4">Genetically mediated thoracic aortic aneurysm and dissection</span><span class="headingEndMark"> — </span>Genetically mediated TAAD can be part of a syndrome (ie, syndromic) such as Marfan syndrome  (<a class="graphic graphic_table graphicRef131337" href="/d/graphic/131337.html" rel="external">table 2</a>), Loeys-Dietz syndrome, vascular Ehlers-Danlos syndrome, or Turner syndrome, or nonsyndromic, as with familial TAAD and bicuspid aortic valve [<a href="#rid30">30,31</a>]. Prophylactic surgery in the setting of many hereditary TAA disorders is uncertain and may depend upon the specific mutation, aneurysm location, family history, absolute aortic size, and growth rate. It is recognized that TAA due to mutations in <em>SMAD3</em>, <em>ACTA2</em>, and <em>MYLK</em> may lead to dissection at relatively small aortic diameters  (<a class="graphic graphic_figure graphicRef115223" href="/d/graphic/115223.html" rel="external">figure 1</a>). Decision making in patients with genetically mediated TAAD, particularly in younger patients (&lt;60 years old), takes into account the diameter of the ascending aorta/proximal arch but also the diameter of the aortic root and aortic valve function  (<a class="graphic graphic_table graphicRef115163" href="/d/graphic/115163.html" rel="external">table 1</a>) [<a href="#rid32">32</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Marfan syndrome</strong> – Marfan patients should generally undergo elective operation at a smaller aortic diameter than patients with degenerative aortic aneurysms to reduce the risk of TAA complications [<a href="#rid3">3,4,33,34</a>]. Surgery is warranted to replace the aortic root and ascending aorta for aortic root diameter of ≥4.5 cm and features associated with an increased risk of aortic dissection, a family history of aortic dissection, rapid aortic expansion (&gt; 0.3 mm per year), diffuse aortic root and ascending aortic dilation, and marked vertebral artery tortuosity. Elective repair at a smaller ascending aortic diameter in surgical centers with expertise in the repair of the aortic root and ascending aorta is reasonable [<a href="#rid3">3,5,35,36</a>]. (See  <a class="medical medical_review" href="/d/html/8151.html" rel="external">"Management of Marfan syndrome and related disorders"</a> and  <a class="medical medical_review" href="/d/html/8129.html" rel="external">"Heritable thoracic aortic diseases: Pregnancy and postpartum care"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bicuspid aortic valve</strong> – A decision for elective repair in patients with bicuspid-aortic-valve-associated aortic dilation depends upon the diameter of the ascending aorta but also on the functional status of the valve [<a href="#rid37">37-41</a>]. Although the aortic valve eventually requires replacement in over 75 percent of patients due to progressive aortic stenosis and/or regurgitation, bicuspid aortic valve is often associated with ascending aortic aneurysm in the absence of significant valvular disease. For some patients, repair of TAA becomes necessary before aortic valve operation is indicated [<a href="#rid42">42</a>]. For asymptomatic patients with bicuspid aortic valve, an ascending aortic diameter &gt;5.5 cm warrants repair (lower for smaller stature); however, for patients with additional risk factors for complications (eg, family history of aortic dissection, rapid expansion &gt;0.5 cm/year), repair at an ascending aortic diameter 5.0 to 5.5 cm, or &gt;4.5 cm in those with severe aortic stenosis or regurgitation, is reasonable to reduce the risk for complications [<a href="#rid5">5</a>]. For those at low risk for aneurysm resection with surgery performed in a center with expertise, surgery at &gt;5.0 cm can be considered [<a href="#rid10">10</a>]. This recommendation is based on data from single-center observational studies of patients who underwent aortic valve replacement for valvular dysfunction. Patients with ascending aortic diameter of 4.0 to 4.5 cm at the time of isolated aortic valve replacement had an increased risk of ascending aortic complications [<a href="#rid3">3,43</a>]. Another retrospective study has also shown that the probability of aortic dissection increases dramatically at an ascending aortic diameter of 5.3 cm and increases gradually at a sinus diameter of 5.0 cm [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/d/html/8155.html" rel="external">"Bicuspid aortic valve: General management in adults"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Loeys Dietz syndrome</strong> – The Loeys-Dietz syndrome has the smallest recommended diameter threshold among the genetically mediated TAA syndromes owing to its aggressive natural history. Prophylactic aortic root and ascending aortic replacement is generally recommended for ascending aortic diameter between 4.0 to 4.5 cm [<a href="#rid4">4,30,45</a>]. However, the decision also depends on the specific genetic variant (eg, <em>SMAD3</em>, <em>TGFB2</em>, <em>TGFB3</em>, <em>MYH11</em>, <em>MLCK</em> and <em>PRKG1</em>), and other factors such as aortic expansion rate, family history, patient age, and sex [<a href="#rid7">7</a>]. (See <a class="local">'Rapid expansion'</a> below and  <a class="medical medical_review" href="/d/html/8151.html" rel="external">"Management of Marfan syndrome and related disorders", section on 'Management of related conditions'</a>.)</p><p></p><p class="headingAnchor" id="H3877225"><span class="h4">Accounting for body size</span><span class="headingEndMark"> — </span>Absolute diameter criteria for intervention on the aorta do not take into account natural variation in aortic diameter for sex and body size  (<a class="graphic graphic_figure graphicRef97883 graphicRef97882" href="/d/graphic/97883.html" rel="external">figure 2A-B</a>). As an example, a small individual (body surface area [BSA] 1.5 m<sup>2</sup>) with an aortic measurement of 4.5 cm may be at a higher risk for aortic complications compared with a larger individual with a BSA of 2.1 and the same aortic measurement. As such, smaller patients may have a smaller diameter threshold for elective intervention due to the larger relative aneurysm diameter. The role of body size has also been evaluated in patients with Marfan syndrome, who tend to be taller [<a href="#rid4">4</a>]. </p><p>One suggested criterion for smaller patients is to perform elective repair for aortic diameters greater than twice the diameter of a normal segment of aorta (nonaneurysmal segment). For smaller patients, including many females, we suggest elective repair using this criterion.</p><p>While not addressed in the later guidelines [<a href="#rid46">46</a>], some have suggested using an indexing method that helps correct for body size. Elective ascending aortic repair is recommended <strong>before</strong> the ascending aortic size (ASI) index (aortic diameter [cm] divided by body surface area [m<sup>2</sup>]) is 2.75 cm/m<sup>2</sup> [<a href="#rid9">9</a>]. Additional investigation has explored the possible importance of using height alone, consisting of the aortic height index (AHI [cm/m]), which may be more predictive of aneurysm complications compared with using BSA [<a href="#rid47">47</a>]. However, this approach has not been widely adopted clinically. </p><p>Another method to account for body size suggests that for cases of Marfan syndrome, it may be reasonable to perform elective aortic root replacement for patients with an ascending aortic area (cm<sup>2</sup>) to height (m) ratio of 10 cm<sup>2</sup>/m [<a href="#rid4">4,5,48</a>]. This index is also being used for those with bicuspid aortic valve-associated aneurysm [<a href="#rid49">49</a>]. </p><p class="headingAnchor" id="H3877273"><span class="h3">Rapid expansion</span><span class="headingEndMark"> — </span>Once a TAA develops, the natural history is one of progressive enlargement with variable expansion rates [<a href="#rid50">50-52</a>]. Expansion rates range from 1 to 10 mm per year, depending upon TAA etiology, diameter, and location within the aorta [<a href="#rid17">17,18,21,50,53-56</a>]. Rapid expansion is defined as ≥0.5 cm in one year or ≥0.3 cm per year in two consecutive years for those with sporadic aneurysms, and ≥0.3 cm in one year for those with heritable thoracic aortic disease or bicuspid aortic valve. Although, rapid expansion is very rare in the absence of an aortic dissection.</p><p>Reports of rapid expansion can reflect measurement errors; however, when rapid expansion is seen, it should raise concern for aortic dissection or aortic infection [<a href="#rid21">21</a>]. Rapid expansion increases the risk of TAA complications; thus, we suggest repair of asymptomatic ascending TAA &lt;5 cm that exhibits rapid expansion, defined as ≥5 mm per year [<a href="#rid4">4,5,11,57</a>]. It is important to note that follow-up should be at the same institution, on the same scanner, so that interobserver variability in assessing size or changes in size does not come into the decision-making process to justify a high-risk operation. </p><p>Similar to abdominal aortic aneurysm, larger-diameter TAAs expand more rapidly than smaller-diameter TAAs [<a href="#rid58">58</a>]. This was illustrated in a study of 67 patients with TAA who underwent serial computed tomography (CT) [<a href="#rid54">54</a>]. The rate of expansion for aneurysms &gt;5.0 cm in diameter at diagnosis was 7.9 mm per year but was approximately 1.7 mm per year for aneurysms &lt;5.0 cm. A history of hypertension did not affect the rate of aneurysm expansion. However, these studies are older, and the location and specific etiology of the aneurysm may not have been taken into account. Larger-diameter aortas (&gt;5.0 cm at the time of diagnosis) can have expansion rates up to 15 mm/year  (<a class="graphic graphic_figure graphicRef59360" href="/d/graphic/59360.html" rel="external">figure 3</a>). </p><p>The anatomic location of the aneurysm is another factor associated with the rate of expansion. In a series of 87 patients who underwent vascular imaging, aneurysms located within the mid-portion of the descending aorta showed the most rapid expansion, while those in the ascending aorta had the slowest expansion rate, despite having a greater initial diameter  (<a class="graphic graphic_figure graphicRef51157" href="/d/graphic/51157.html" rel="external">figure 4</a>) [<a href="#rid53">53</a>]. In general, isolated degenerative ascending aortic aneurysms have an average expansion rate of 1 mm per year, whereas descending TAAs expand by approximately 3 mm per year [<a href="#rid58">58,59</a>]. </p><p>Saccular aneurysm morphology is associated with aortic infection and increased rates of expansion and rupture compared with fusiform. In one study, the expansion rate of saccular aneurysms was 28 mm/year [<a href="#rid60">60</a>]. As such, saccular aneurysms are often treated more aggressively. </p><p>Patients with familial TAAs have faster average rates of expansion at 2 mm per year (combined ascending and descending TAA) [<a href="#rid58">58,61-64</a>]. Marfan syndrome is associated with expansion rates of up to 3 mm per year. An increased aortic expansion rate has also been reported during pregnancy for those with Marfan syndrome compared with those with Marfan syndrome who are not pregnant both during and following pregnancy, in some but not all studies [<a href="#rid65">65-68</a>]. TAAs associated with the particularly aggressive Loeys-Dietz syndrome can expand very rapidly up to 10 mm per year [<a href="#rid45">45</a>]. </p><p class="headingAnchor" id="H277993201"><span class="h1">MANAGEMENT OF ASYMPTOMATIC TAA</span><span class="headingEndMark"> — </span>Asymptomatic thoracic aortic aneurysms (TAAs) may be detected on routine chest radiograph or during surveillance in a patient with an underlying genetically mediated condition such as Marfan syndrome. (See  <a class="medical medical_review" href="/d/html/8192.html" rel="external">"Clinical manifestations and diagnosis of thoracic aortic aneurysm", section on 'Incidental TAA'</a>.) </p><p>Asymptomatic patients without indications for repair are managed conservatively, which includes the following (see <a class="local">'Indications for repair'</a> above):  </p><p class="bulletIndent1"><span class="glyph">●</span>Measures to reduce cardiovascular risk. (See <a class="local">'Cardiovascular risk reduction'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Aggressive blood pressure control (≤130 mmHg), and other measures to limit aneurysm expansion. Beta-blockers are the first-line therapy. Angiotensin receptor blockers are a reasonable adjunct to beta blockers to achieve adequate blood pressure control. (See <a class="local">'Antihypertensive therapies'</a> below and <a class="local">'Therapies to limit aortic expansion'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Statin therapy is reasonable in those with thoracic aortic aneurysm. (See <a class="local">'Statin therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient education regarding the symptoms and signs that may indicate the development of complications. (See <a class="local">'Counseling and other evaluation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Counseling for those suspected of having genetically mediated disease. First-degree relatives of those with TAA disease should be screened, based on family studies demonstrating an approximately 20 percent chance of another first-degree relative having a TAA [<a href="#rid58">58,61</a>]. (See <a class="local">'Identifying associated genetic conditions'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Screening for associated aneurysmal disease. (See <a class="local">'Identifying associated aneurysm'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serial imaging of the aneurysm to evaluate for expansion and changes in extent. (See <a class="local">'Aneurysm surveillance'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Counseling on exercise and activity limitations is individualized, but in general, contact sports are avoided and most patients are counseled against heavy lifting (defined as half of ideal body weight) and exercises involving sustained Valsalva maneuver. </p><p></p><p class="headingAnchor" id="H277993510"><span class="h2">Cardiovascular risk reduction</span><span class="headingEndMark"> — </span>Managing cardiovascular risk is important for improving overall outcomes, including outcomes associated with aortic repair, when it is required. Lifestyle modification, including smoking cessation, is an important aspect to medical management in these patients [<a href="#rid69">69-71</a>]. Although it is unknown whether statins reduce the rate of thoracic aortic expansion, most patients with TAA have other indications for statin therapy. Statin therapy should be used to meet low-density lipoprotein (LDL) goals as outlined by multidisciplinary guidelines [<a href="#rid4">4,5</a>]. (See <a class="local">'Statin therapy'</a> below and  <a class="medical medical_review" href="/d/html/7573.html" rel="external">"Overview of primary prevention of cardiovascular disease"</a> and  <a class="medical medical_review" href="/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>.) </p><p>We agree with major society guidelines that advise patients with aneurysmal disease to stop smoking; these patients should be offered cessation interventions [<a href="#rid4">4</a>]. The management of smoking cessation is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/121010.html" rel="external">"Overview of vascular intervention and surgery for vascular anomalies"</a> and  <a class="medical medical_review" href="/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>.)</p><p>Cigarette smoking is strongly associated with aneurysm formation, aneurysm expansion, and aneurysm rupture and is an important modifiable risk factor. Although the majority of studies that have defined these associations have been in patients with abdominal aortic aneurysm (AAA), smoking has also been linked to alterations in mechanical properties of the thoracic aorta in animal models [<a href="#rid72">72</a>]. (See  <a class="medical medical_review" href="/d/html/15188.html" rel="external">"Management of asymptomatic abdominal aortic aneurysm", section on 'Smoking cessation'</a>.)</p><p class="headingAnchor" id="H277993547"><span class="h2">Therapies to limit aortic expansion</span><span class="headingEndMark"> — </span>Much of the data regarding pharmacologic therapy to limit expansion of TAA are derived from mouse model studies, such as fibrillin-1–deficient (Marfan) mice [<a href="#rid69">69,71</a>]. There are emerging studies on the treatment of TAA disease in humans. But, similarly, the majority of these studies have been performed on patients with Marfan syndrome. Whether these results can be generalized to the non-Marfan population is uncertain, but given some shared pathophysiologic pathways, findings of these investigations may indirectly support pharmacologic treatment (antihypertensive therapy, statin therapy) in non-Marfan subpopulations [<a href="#rid71">71,73</a>]. (See  <a class="medical medical_review" href="/d/html/88937.html" rel="external">"Epidemiology, risk factors, pathogenesis, and natural history of thoracic aortic aneurysm and dissection", section on 'Pathogenesis'</a>.)</p><p class="headingAnchor" id="H277994703"><span class="h3">Antihypertensive therapies</span><span class="headingEndMark"> — </span>Based primarily on studies performed in Marfan patients, for patients with asymptomatic TAA who are being conservatively managed, we suggest blood pressure control primarily using beta blocker therapy with the aim of limiting further aortic expansion [<a href="#rid4">4,74,75</a>]. While the theoretical benefit of anti-impulse therapy is widely accepted, no controlled studies have demonstrated a benefit. The goal systolic pressure is 105 to 120 mmHg, if tolerated. The adequacy of beta blockade is usually judged by the heart rate response. An angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) is an acceptable alternative for blood pressure control among those who do not tolerate beta blocker therapy. </p><p>For patients with bicuspid aortic valves and a dilated ascending TAA without moderate or severe aortic regurgitation, guidelines on the treatment of valvular disease suggest any effective antihypertensive to control blood pressure. Beta blockers and ARBs have a conceptual advantage but have not been shown to be effective in clinical studies [<a href="#rid46">46,76</a>]. (See  <a class="medical medical_review" href="/d/html/8150.html" rel="external">"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta blockers</strong> – Beta blockers reduce the inotropic state of the heart, decreasing left ventricular contractility (dP/dt) and shear stress, and the impact force of ejected blood on the aorta [<a href="#rid77">77</a>]. A clinical benefit has been demonstrated only in studies of Marfan patients [<a href="#rid78">78-80</a>]. It is not known if these results can be extrapolated to patients without Marfan syndrome, but it is biologically plausible to attempt such therapy. In a 10 year study in which 70 patients with Marfan syndrome were randomly assigned to <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a> or no beta blocker therapy, the treated group had a 73 percent slower rate of aortic expansion and lower mortality after the first four years of follow-up [<a href="#rid78">78</a>]. A retrospective nonrandomized study of beta blocker use in children with Marfan syndrome also demonstrated a slowing of aortic expansion in patients treated with beta blockers compared with untreated controls [<a href="#rid80">80</a>]. However, some studies suggest that beta blockers do not protect against TAA expansion [<a href="#rid53">53,71,81</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ACE inhibitors and ARBs</strong> – Experimental research suggests a role for the renin-angiotensin pathways in the formation of aneurysms [<a href="#rid80">80,82-84</a>]. Studies on ACE inhibitors and ARBs have reported conflicting results [<a href="#rid71">71,85-91</a>]. ACE inhibition may have beneficial effects by modifying the inflammatory mediators and by decreasing vascular smooth muscle apoptosis [<a href="#rid87">87</a>]. ARBs may also be important in preventing aneurysm expansion in Marfan syndrome due to downregulation of transforming growth factor beta (TGF-beta) and its effects [<a href="#rid88">88,89</a>]. <a class="drug drug_general" data-topicid="9574" href="/d/drug information/9574.html" rel="external">Losartan</a> may have a protective effect by antagonizing the activity of transforming growth factor (TGF) [<a href="#rid88">88</a>]. In a nonrandomized study of young patients with Marfan syndrome and aortic root dilation, ARB therapy significantly reduced the rate of aortic expansion [<a href="#rid88">88</a>]. Another study reported no benefit of an angiotensin-receptor blocker (Losartan) over a beta blocker (<a class="drug drug_general" data-topicid="8940" href="/d/drug information/8940.html" rel="external">atenolol</a>) with respect to the rate of aortic-root dilation in patients with Marfan syndrome [<a href="#rid90">90</a>]. One interpretation of this study is that ARBs are as effective as beta blockers in the treatment of patients with Marfan syndrome; however, such an interpretation assumes that beta blockers are an effective treatment option. (See  <a class="medical medical_review" href="/d/html/8151.html" rel="external">"Management of Marfan syndrome and related disorders", section on 'Drug therapy'</a>.)</p><p></p><p class="headingAnchor" id="H182188293"><span class="h3">Statin therapy</span><span class="headingEndMark"> — </span>Although mostly studied in the context of AAA [<a href="#rid92">92-95</a>], statin therapy may provide a protective effect by inhibiting matrix metalloproteinases (MMPs) and plasminogen activator [<a href="#rid96">96</a>]. In a Marfan mouse model, <a class="drug drug_general" data-topicid="9804" href="/d/drug information/9804.html" rel="external">pravastatin</a> was found to attenuate aortic root aneurysm formation [<a href="#rid97">97</a>]. In one retrospective review of TAA patients, mortality rates were significantly lower among those taking statins compared with those who were not (20 versus 33 percent); this effect was independent of angiotensin blockade [<a href="#rid98">98</a>]. Survival was attributed to a decreased need for surgical repair due to reduced aortic expansion. In another retrospective review, statin therapy was associated with a significant reduction in complications, including aortic dissection [<a href="#rid96">96,99</a>]. </p><p class="headingAnchor" id="H277998598"><span class="h3">Other pharmacologic therapies</span><span class="headingEndMark"> — </span>There are no data reporting a benefit for any other pharmacologic therapy for limiting aortic expansion for TAA in humans. </p><p><a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> also reduces matrix metalloproteinase (MMP) activity, and thus elastin destruction, and has been shown to prevent aortic root aneurysm in fibrillin-1-deficient mice [<a href="#rid100">100</a>]. Small studies using doxycycline have demonstrated attenuation of AAA expansion in human subjects. (See  <a class="medical medical_review" href="/d/html/15188.html" rel="external">"Management of asymptomatic abdominal aortic aneurysm", section on 'Doxycycline'</a>.)</p><p class="headingAnchor" id="H1222335403"><span class="h2">Avoidance of fluoroquinolones</span><span class="headingEndMark"> — </span>Fluoroquinolones have been linked to an increased risk of aortic dissection and aneurysm rupture [<a href="#rid101">101</a>]. The US Food and Drug Administration (FDA) has issued a safety advisory that this class of drugs should be avoided in patients with aortic aneurysm or who are at risk for aortic aneurysm [<a href="#rid102">102</a>]. (See  <a class="medical medical_review" href="/d/html/88937.html" rel="external">"Epidemiology, risk factors, pathogenesis, and natural history of thoracic aortic aneurysm and dissection", section on 'Rupture/dissection'</a> and  <a class="medical medical_review" href="/d/html/15188.html" rel="external">"Management of asymptomatic abdominal aortic aneurysm", section on 'Fluoroquinolone use'</a>.)</p><p class="headingAnchor" id="H4174666573"><span class="h2">Aneurysm surveillance</span><span class="headingEndMark"> — </span>Asymptomatic patients who do not meet the diameter criteria for elective TAA repair (open or endovascular) require long-term aneurysm surveillance. Aneurysm surveillance includes ongoing clinical evaluation for the development of symptoms and signs of aneurysm complications, and serial imaging to evaluate the diameter and structure of the aneurysm. The preferred imaging technique depends on the location of the aortic aneurysm; options include echocardiography, CT angiography, or magnetic resonance (MR) angiography. Ideally, the serial studies should be performed using the same technique in the same center for consistency with future comparisons [<a href="#rid103">103</a>]. If a TAA is only moderate in size <strong>and</strong> remains relatively stable over time, MR rather than CT is reasonable to minimize the patient's radiation exposure [<a href="#rid4">4,5</a>]. </p><p>In general, we suggest imaging at six months after the initial diagnosis to ensure the stability of the aneurysm diameter and extent [<a href="#rid4">4,52,57</a>]. Further imaging can be performed annually if there is no expansion or extension. However, the surveillance schedule may be modified based upon the etiology, site, and diameter of the aneurysm at presentation. If the aorta demonstrates rapid expansion or is approaching the threshold for surgery or endovascular repair, we suggest more frequent imaging at every three to six months. </p><p>A proposed approach to imaging these patients was adapted from guidelines on the management of thoracic aortic disease [<a href="#rid7">7</a>] . </p><p class="bulletIndent1"><span class="glyph">●</span>Degenerative aortic root or ascending aortic aneurysm:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>3.5 to 4.4 cm: Annual CT or MR angiography, echocardiogram to follow valvular disease (if needed)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>4.5 to 5.4 cm: Biannual (every six months) CT or MR angiography, echocardiogram to follow valvular disease (if needed)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetically mediated aortic root or ascending aortic aneurysm: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>3.5 to 4.4 cm: Annual echocardiogram, CT, or magnetic resonance imaging (MRI)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>4.5 to 5.0 cm: Biannual (every six months) echocardiogram, CT, or MRI</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Descending aortic aneurysm: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>4.0 to 4.9 cm: Annual CT or MR angiography</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>5.0 to 6.0 cm: Biannual (every six months) CT or MR angiography</p><p></p><p>When an aortic root or ascending aortic aneurysm is present, transthoracic echocardiogram should be performed to evaluate for the presence of a bicuspid aortic valve (BAV), one of the most common causes of a dilated aorta [<a href="#rid3">3,5</a>]. It is also important to consider body size when evaluating the significance of aortic root dimensions [<a href="#rid4">4</a>]. (See <a class="local">'Accounting for body size'</a> above.)</p><p class="headingAnchor" id="H360830072"><span class="h1">COUNSELING AND OTHER EVALUATION</span></p><p class="headingAnchor" id="H278008193"><span class="h2">Identifying associated genetic conditions</span><span class="headingEndMark"> — </span>Patients identified as having thoracic aortic aneurysm or dissection (TAAD) should be evaluated for possible underlying genetic or familial disorders known to be related to TAAD, which may increase their individual risk of aneurysm progression or complications. The evaluation should include a thorough family history to evaluate for sudden or unexplained death and history of aneurysm or dissection. (See  <a class="medical medical_review" href="/d/html/88937.html" rel="external">"Epidemiology, risk factors, pathogenesis, and natural history of thoracic aortic aneurysm and dissection", section on 'Genetic predisposition'</a>.)</p><p>TAA can occur as part of complex genetic syndromes, such as Marfan syndrome (most common), Ehlers-Danlos syndrome, Loeys-Dietz syndrome, and Turner syndrome. However, increasing numbers of genetic loci have been linked to nonsyndromic familial TAAD<em> </em>and suggest that the true proportion of familial TAADs is approximately 20 percent [<a href="#rid104">104,105</a>]. </p><p>Young age at presentation is an important clue that a patient has genetically mediated TAAD. In a retrospective review at a single institution of 760 patients between 16 and 60 years of age diagnosed with aortopathy, differences in presentation and outcomes were studied [<a href="#rid106">106</a>]. The etiology of genetically mediated TAAD was nonsyndromic TAA in 311, Marfan syndrome in 221, and bicuspid aortic valve disease in 228. The average age was 37. Marfan patients were younger than nonsyndromic TAA and bicuspid aortic valve patients. However, a symptomatic presentation with aortic dissection was more common for nonsyndromic TAA compared with Marfan syndrome or bicuspid aortic valve. (See  <a class="medical medical_review" href="/d/html/8192.html" rel="external">"Clinical manifestations and diagnosis of thoracic aortic aneurysm", section on 'Determining TAA etiology'</a>.) </p><p>If one or more first-degree relatives of a patient with known TAAD are found to have thoracic aortic dilatation, aneurysm, dissection, an abdominal aortic aneurysm, or brain aneurysm, then referral to a geneticist is recommended. First-degree relatives of those with TAA disease should be screened, based on family studies demonstrating an approximately 20 percent chance of another first-degree relative having a TAA [<a href="#rid58">58,61</a>]. Family members (siblings, children) may also require screening. For those with a positive family history, genetic testing can be based on phenotypes most commonly associated with TAA, when they are present  (<a class="graphic graphic_algorithm graphicRef105596" href="/d/graphic/105596.html" rel="external">algorithm 1</a>) [<a href="#rid107">107</a>]. A panel of genes can be checked in those patients who do not have clinical characteristics that suggest a specific syndrome. </p><p>The 2022 American College of Cardiology (ACC)/American Heart Association (AHA) Aortic Disease Guidelines recommend genetic testing for aortopathy in the following scenarios [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Obtain a complete aortic family history in patients with aortic root/ascending thoracic aortic disease (TAD) or thoracic aortic aneurysm or dissection (ie, TAAD)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obtain testing for genetic aortopathy in patients with TAD or TAAD age &lt;60 years, family history of TAD or intracranial aneurysm, and those with phenotypic features of genetic aortopathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with positive genetic testing:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Obtain cascade testing of at-risk biologic relatives.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Obtain transthoracic echocardiogram or CT angiography to screen for aneurysm in family members with positive genetic testing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Provide genetic counseling for positive aortopathy screening.</p><p></p><p>Inheritance patterns for familial bicuspid aortic valve associated with TAA are consistent with an autosomal dominant pattern with incomplete penetrance [<a href="#rid108">108</a>]. Recommendations for screening are discussed separately. (See  <a class="medical medical_review" href="/d/html/8157.html" rel="external">"Clinical manifestations and diagnosis of bicuspid aortic valve in adults", section on 'Genetics'</a>.)</p><p class="headingAnchor" id="H278008157"><span class="h2">Identifying associated aneurysm</span><span class="headingEndMark"> — </span>Thoracic aortic aneurysm is associated with aneurysmal disease affecting other vascular beds. This association is likely related to a common pathophysiology, which is distinct from that of the ascending aorta [<a href="#rid109">109</a>]. As such, we have a low threshold to screen TAA patients for abdominal aortic aneurysm (AAA), intracranial aneurysm, and aneurysms affecting the lower extremities (iliac, femoral, popliteal). For patients with Loeys-Dietz syndrome, head-to-pelvis imaging is recommended upon diagnosis and periodically thereafter. (See  <a class="medical medical_review" href="/d/html/88937.html" rel="external">"Epidemiology, risk factors, pathogenesis, and natural history of thoracic aortic aneurysm and dissection", section on 'Pathogenesis'</a>.)</p><p>AAA is present in approximately 20 percent of patients diagnosed with TAA [<a href="#rid110">110</a>]. In an imaging review, AAA was more positively associated with arch and descending TAAs, particularly those located near the diaphragm [<a href="#rid110">110</a>]. The associations of lower extremity aneurysms with AAA and TAA are reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/15229.html" rel="external">"Clinical features and diagnosis of abdominal aortic aneurysm", section on 'Imaging asymptomatic patients'</a> and  <a class="medical medical_review" href="/d/html/15703.html" rel="external">"Iliac artery aneurysm"</a> and  <a class="medical medical_review" href="/d/html/15187.html" rel="external">"Popliteal artery aneurysm"</a>.) </p><p>TAA is also associated with intracranial aneurysm (ICA). In a review of 212 patients with TAA, the prevalence of ICA was 9.0 percent, which was ninefold greater than that in the general population [<a href="#rid111">111</a>]. (See  <a class="medical medical_review" href="/d/html/1135.html" rel="external">"Screening for intracranial aneurysm"</a>.)</p><p class="headingAnchor" id="H3054172779"><span class="h2">Counseling the high-risk patient</span><span class="headingEndMark"> — </span>Asymptomatic patients with TAA meeting criteria for repair who have severe medical comorbidities who are judged to be high risk for repair (open surgical or endovascular) may be best managed conservatively, reserving repair only if symptoms develop (including rupture). </p><p>Patient with Marfan syndrome who are pregnant, bicuspid aortic valve, Ehlers-Danlos syndrome, and Loeys-Dietz syndrome have an increased risk for complications related to TAA [<a href="#rid112">112</a>]. Counseling females with TAA regarding the risks of pregnancy and determining the timing of repair relative to planned pregnancy is discussed separately. (See <a class="local">'Symptomatic (nonruptured) and ruptured TAA'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8129.html" rel="external">"Heritable thoracic aortic diseases: Pregnancy and postpartum care"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1425.html" rel="external">"Bicuspid aortic valve: Management during pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/89916.html" rel="external">"Overview of the management of Ehlers-Danlos syndromes", section on 'Reproductive options and pregnancy'</a>.)</p><p></p><p>Recommendations for activity and sports participation among patients with connective tissue disorders, including Marfan syndrome, are discussed separately. (See  <a class="medical medical_review" href="/d/html/8151.html" rel="external">"Management of Marfan syndrome and related disorders", section on 'Restriction of strenuous activity'</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">THORACIC ANEURYSM REPAIR</span><span class="headingEndMark"> — </span>Prophylactic repair of thoracic aortic aneurysm (TAA) for appropriate diameter/expansion criteria is recommended to prevent the morbidity and mortality associated with aneurysm rupture/dissection. The five-year survival rate after elective open surgical repair of a TAA in contemporary series is approximately 85 percent. Emergency surgery for TAA complications has much worse outcomes, with a five-year survival rate of 37 percent [<a href="#rid17">17</a>]. There are no trials comparing endovascular repair versus medical management, but long-term survival is expected to be similar to open repair. (See <a class="local">'Open versus endovascular repair of descending TAA'</a> below.) </p><p>The timing of repair for a particular individual with TAA is individualized since the natural history is variable, particularly for aneurysms &lt;5.0 cm in diameter [<a href="#rid17">17</a>], and the majority of patients have concomitant cardiovascular disease that increases the risks associated with surgery. Many patients die of other cardiovascular causes before the aneurysm ruptures. (See <a class="local">'Indications for repair'</a> above.)</p><p>Where expertise in the management of thoracic aortic disease is not available, the patient with TAA should be referred (or transferred for symptomatic patients) to a high-volume cardiovascular center to provide the best possible outcome [<a href="#rid6">6</a>]. </p><p>Prior to TAA repair, the patient should undergo cardiovascular risk assessment. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6616.html" rel="external">"Evaluation of cardiac risk prior to noncardiac surgery"</a>.)</p><p>In addition:</p><p class="bulletIndent1"><span class="glyph">●</span>Preoperative assessment should include evaluation of left ventricular function, valve disease, and potential concomitant coronary artery disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with ascending aortic and particularly arch disease should undergo carotid artery duplex ultrasound examination. (See  <a class="medical medical_review" href="/d/html/1118.html" rel="external">"Evaluation of carotid artery stenosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with descending thoracic aortic disease who require left thoracotomy should undergo pulmonary function testing if clinical symptoms of pulmonary disease are present. (See  <a class="medical medical_review" href="/d/html/6969.html" rel="external">"Overview of pulmonary function testing in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with TAA that extends distally should be assessed for symptoms and signs of peripheral artery disease. If present, noninvasive lower extremity pulse-volume recordings and pressures will determine the level and severity of disease to serve as a baseline for future comparison. (See  <a class="medical medical_review" href="/d/html/8201.html" rel="external">"Noninvasive diagnosis of upper and lower extremity arterial disease"</a>.)</p><p></p><p class="headingAnchor" id="H182191374"><span class="h2">Approach to repair</span><span class="headingEndMark"> — </span>Ascending TAA is managed with an open surgical approach using cardiopulmonary bypass and sometimes requires aortic root replacement with coronary artery reimplantation. Descending TAA can be repaired with an open or endovascular approach, or a combination of the two (hybrid repair). </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Open surgery</strong> – The nature of open surgery varies depending upon the location and extent of the aneurysm. Open repair of ascending TAA is performed via a median sternotomy with cardiopulmonary bypass including cardioplegia and often requires aortic root replacement or coronary artery reimplantation. The diseased aortic segment is typically replaced with either a composite graft (ie, aortic valve replaced) or valve-sparing procedure [<a href="#rid113">113</a>]. For bicuspid aortic valve, the valve can be replaced or repaired at the time of aortic surgery [<a href="#rid114">114</a>]. When the aortic arch is involved, hypothermic circulatory arrest needs to be instituted typically with antegrade or retrograde cerebral perfusion. The aortic arch can be repaired via a hemi-arch technique or total arch replacement. Open repair of descending TAA is via a left thoracotomy and often does not require full cardiopulmonary bypass or cardioplegia; however, measures to protect the spinal cord are important. End-organ revascularization (visceral, renal) may require native arterial reimplantation with or without endarterectomy, or bypass grafting. (See  <a class="medical medical_review" href="/d/html/88951.html" rel="external">"Overview of open surgical repair of the thoracic aorta"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endovascular repair</strong> – Thoracic endovascular aneurysm repair involves the placement of modular graft components delivered via the iliac or femoral arteries to line the descending thoracic aorta and exclude the aneurysm from the circulation. Endovascular repair requires fulfillment of specific anatomic criteria, and the greatest experience involves treatment of descending TAA that does not involve the abdominal visceral segment. The role of stent-grafting for extensive thoracoabdominal aortic disease, which requires debranching procedures or specialized grafts (fenestrated, branched endografts), is an area of active clinical research. Although endovascular repair is associated with lower perioperative mortality, late complications, including graft migration and aortic rupture, have been reported. Newer generation endografts specifically designed for use in the aortic arch, both single-branch and multi-branch, are in clinical trials for use in arch pathology. (See  <a class="medical medical_review" href="/d/html/8191.html" rel="external">"Endovascular repair of the thoracic aorta"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hybrid repair</strong> – A hybrid approach involves typically an open approach to manage the ascending aorta or aortic arch, with an endovascular approach for the descending thoracic aorta (ie, frozen elephant trunk) [<a href="#rid115">115-123</a>]. (See  <a class="medical medical_review" href="/d/html/88951.html" rel="external">"Overview of open surgical repair of the thoracic aorta"</a>.)</p><p></p><p class="headingAnchor" id="H354445832"><span class="h2">Open versus endovascular repair of descending TAA</span><span class="headingEndMark"> — </span>The choice of approach to repair (open versus endovascular) for descending TAA should take into account the etiology (degenerative, genetically mediated, infectious), location in the descending aorta, and extent of the aneurysm, and the patient's expected survival (short-term and long-term), which depends upon the patient's age and medical comorbidities. </p><p class="headingAnchor" id="H3799777026"><span class="h3">Degenerative versus genetically mediated aneurysm</span><span class="headingEndMark"> — </span>Thoracic aortic aneurysm/dissection can be degenerative or related to genetically mediated disorders (nonsyndromic or syndromic). The etiology of descending aneurysmal disease determines the preferred approach to repair. (See  <a class="medical medical_review" href="/d/html/8192.html" rel="external">"Clinical manifestations and diagnosis of thoracic aortic aneurysm", section on 'Determining TAA etiology'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with <strong>degenerative</strong> descending TAA (asymptomatic, symptomatic) that does not involve the visceral segment, and anatomy that is otherwise suitable for endovascular repair, we use an endovascular rather than open surgical approach to repair. Endovascular repair is associated with reduced perioperative morbidity and mortality; however, the long-term durability of endovascular TAA repair compared with open surgical repair remains uncertain. Endovascular repair combined with a debranching procedure may still be an option for distal TAA but cannot generally be performed in an urgent setting given the need for customized endovascular devices. (See <a class="local">'Thoracic aneurysm repair'</a> above and  <a class="medical medical_review" href="/d/html/8191.html" rel="external">"Endovascular repair of the thoracic aorta"</a> and <a class="local">'Elective repair'</a> below and <a class="local">'Emergency repair'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with <strong>syndromic</strong> descending TAA, we use an open surgical approach to replace the descending thoracic aorta, rather than endovascular stent-graft placement. Unfavorable late aortic remodeling at the site of stent-graft placement has been reported, likely related to the persistent radial force of these devices against the abnormal aortic tissue. However, some feel that stent-grafting may be justified in emergencies as a "bridging" method to later definitive surgical repair, though elective repair has also been reported [<a href="#rid124">124</a>]. The optimal approach for those with <strong>nonsyndromic</strong> TAA is still unknown as there are no large data sets evaluating stent grafting in nonsyndromic TAA. Therefore, depending on the extent of repair needed, patient age, and other comorbidities, either approach may be appropriate. (See  <a class="medical medical_review" href="/d/html/8191.html" rel="external">"Endovascular repair of the thoracic aorta", section on 'Contraindications'</a>.)</p><p></p><p class="headingAnchor" id="H4049623029"><span class="h3">Elective repair</span><span class="headingEndMark"> — </span>There are no randomized trials comparing endovascular with open surgery for the repair of descending TAA, but the bulk of the evidence from observational studies argues for an endovascular rather than open approach in those patients who are candidates for both, largely due to the 30 day morbidity and mortality benefit [<a href="#rid125">125-127</a>]. Long-term durability continues to be the main concern as the rate of secondary endovascular interventions following thoracic stent-grafting ranges from 10 to 32 percent, while the rate of secondary open operation ranges anywhere from 0.4 to 7.9 percent [<a href="#rid128">128</a>]. </p><p>Systematic reviews of observational studies have found significantly reduced rates of perioperative morbidity and mortality in the short term (odds ratio [OR] 0.36; 95% CI 0.23-0.58 [<a href="#rid125">125</a>]), and reduced length of hospital stay for an endovascular compared with an open approach [<a href="#rid125">125-127</a>]. The risk of major neurologic injury was also lower for the endovascular approach (OR 0.39; 95% CI 0.25-0.62) [<a href="#rid125">125</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective study comparing thoracic aortic aneurysm endovascular repair with open repair, perioperative events, including myocardial infarction, respiratory events such as pneumonia or ventilation for more than 24 hours, stroke, and paraplegia, were combined into a composite score [<a href="#rid129">129</a>]. The percentage of patients who experienced at least one event was significantly lower in the endovascular group compared with open surgery (9 versus 33 percent). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In two smaller studies, each of which included around 230 patients, perioperative mortality was significantly lower with endovascular repair (2.1 versus 11.7 percent early after surgery, and 1.9 versus 5.7 percent at 30 days) [<a href="#rid129">129,130</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients in the study cited above were followed for five years [<a href="#rid131">131</a>]. Aneurysm-related mortality was lower for endovascular repair (2.8 versus 11.7 percent), most of which was attributable to fewer perioperative deaths. Major adverse events, defined as prolongation of treatment, new hospitalization, major disability, or death, were also lower (58 versus 79 percent). No significant differences were seen for survival (68 versus 67 percent) or the rate of aneurysm-related reintervention (3.6 versus 2.1 percent).</p><p></p><p>Nevertheless, there remain concerns over the validity of these comparisons due to the following concerns [<a href="#rid132">132</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Many studies compare endovascular repair with older surgical techniques or operations with greater extents of repair [<a href="#rid133">133</a>]. In a later single-center retrospective study of over 700 patients who received either endovascular repair or open surgery, mortality was not significantly different at 30 days (5.7 versus 8.3 percent, respectively) and 12 months (15.6 versus 15.9 percent, respectively) [<a href="#rid134">134</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Many patients enrolled in endovascular repair studies were not eligible for open surgery due to comorbidities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Many patients enrolled in open surgery studies include patients who would not be eligible for endovascular repair because of anatomic constraints [<a href="#rid135">135</a>].</p><p></p><p class="headingAnchor" id="H2748293012"><span class="h3">Emergency repair</span><span class="headingEndMark"> — </span>Patients treated for symptomatic TAA (eg, rupture, dissection) have increased perioperative mortality. Among this subpopulation, endovascular repair of symptomatic/ruptured TAA is also associated with improvements in perioperative morbidity and mortality [<a href="#rid136">136-140</a>]. The outcomes of endovascular versus open surgery in the emergency setting were specifically addressed in a nonrandomized study of 60 consecutive patients with acute rupture of the thoracic aorta; 28 patients were treated surgically and 32 were treated with an endovascular stent-graft [<a href="#rid140">140</a>]. The following findings were reported:</p><p class="bulletIndent1"><span class="glyph">●</span>Perioperative mortality was significantly lower with the endovascular approach compared with open surgery (3.1 versus 17.8 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At a mean follow-up of 36 months, four additional deaths occurred in patients who received stent-grafts; three were attributed to late procedural complications (one aneurysm, one dissection, and one traumatic transection). No additional procedure-related deaths occurred in the surgical patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reintervention rates were similar between the groups. All of the surgical reinterventions were early in the postoperative course for bleeding. In the patients treated with stent-grafts, one required early drainage of an empyema, and two required late interventions for endovascular leaks (one repeat stent, complicated by paraplegia; one surgical repair with stent-graft removal).</p><p></p><p class="headingAnchor" id="H2348980586"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118036.html" rel="external">"Society guideline links: Aortic and other peripheral aneurysms"</a>.)</p><p class="headingAnchor" id="H1025911875"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/112893.html" rel="external">"Patient education: Thoracic aortic aneurysm (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H757960246"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient evaluation</strong> –<strong> </strong>Patients diagnosed with thoracic aortic aneurysm (TAA) should be evaluated for possible underlying genetic syndromes known to be related to thoracic aortic aneurysm and dissection (TAAD). The patient should also be evaluated for other associated aneurysms (eg, brain, abdominal aorta, mesenteric, iliac, femoral, or popliteal arteries) using CT angiography or ultrasound. Among symptomatic patients, this evaluation is obtained postoperatively. (See <a class="local">'Management of asymptomatic TAA'</a> above and <a class="local">'Identifying associated genetic conditions'</a> above and <a class="local">'Identifying associated aneurysm'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Repair of symptomatic TAA</strong> – Patients who develop symptoms attributable to TAA should undergo urgent repair (open surgical, endovascular), provided the risk for repair is not prohibitive. Symptoms in a patient with TAA (known or unknown) like chest pain can represent rapid aneurysm expansion or be due to a variety of life-threatening complications, including aortic dissection, acute aortic regurgitation, aortic leakage, or overt aortic rupture. (See <a class="local">'Symptomatic (nonruptured) and ruptured TAA'</a> above and  <a class="medical medical_review" href="/d/html/8192.html" rel="external">"Clinical manifestations and diagnosis of thoracic aortic aneurysm", section on 'Symptomatic TAA'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surveillance and medical management of</strong> <strong>asymptomatic TAA</strong> – Most TAAs produce no symptoms; however, the natural history of TAA is one of progressive expansion, which depends upon the location and diameter of the aneurysm and its underlying etiology. Aneurysm diameter is the most important factor determining the risk for TAA complications. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with asymptomatic TAA should be followed for the development of signs and symptoms that may be associated with the TAA. The surveillance schedule is based upon the etiology, site, and diameter of the aneurysm at presentation, and expansion rates identified at follow-up. Ideally, serial CT or magnetic resonance (MR) angiography studies should be performed using the same imaging technique at the same center. (See <a class="local">'Aneurysm surveillance'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Following the initial study that identified TAA, we suggest imaging six months after the initial study to ensure the stability of the aneurysm diameter and extent. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If the TAA does not demonstrate expansion after six months, we suggest annual imaging. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If the TAA demonstrates expansion or is approaching the diameter threshold for repair, we suggest imaging every three to six months. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with asymptomatic TAA who are being conservatively managed, control of hypertension is recommended to limit further aortic expansion. We suggest beta blocker therapy rather than other agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The goal systolic pressure is 105 to 120 mmHg, if tolerated. An angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) for blood pressure control is an acceptable alternative for those who do not tolerate beta blocker therapy. Most patients have concomitant cardiovascular disease; thus, managing cardiovascular risk factors (eg, smoking cessation, antiplatelet therapy, statin therapy) is also important. Statin therapy may also reduce adverse outcomes related to TAA. (See <a class="local">'Antihypertensive therapies'</a> above and <a class="local">'Management of asymptomatic TAA'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Repair of asymptomatic TAA</strong> – Elective repair of asymptomatic TAA is not undertaken until the risk of rupture or other complications exceeds the risks associated with repair. For most patients with asymptomatic TAA, we use the defined threshold criteria defined above for elective repair  (<a class="graphic graphic_table graphicRef115163" href="/d/graphic/115163.html" rel="external">table 1</a>). Candidates for elective repair are selected based upon diameter, location, expansion rate, and patient comorbidities, accounting the presence of underlying contributing etiologies. For patients who do not meet the defined criteria, we suggest not performing elective repair (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). These patients are followed conservatively and are considered for repair if symptoms develop. (See <a class="local">'Summary of indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to TAA repair</strong> – The approach to TAA repair (open, endovascular) takes into account the location and anatomic extent of the aneurysm, etiology, and the patient's expected survival (short-term and long-term), which depends upon the patient's age and medical comorbidities. (See <a class="local">'Thoracic aneurysm repair'</a> above and  <a class="medical medical_review" href="/d/html/8191.html" rel="external">"Endovascular repair of the thoracic aorta"</a> and  <a class="medical medical_review" href="/d/html/88951.html" rel="external">"Overview of open surgical repair of the thoracic aorta"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ascending TAA is traditionally managed with an open surgical approach using cardiopulmonary bypass and often requires aortic root replacement and/or coronary artery reimplantation. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Descending TAA can be repaired with an open or endovascular approach, the choice of which depends upon whether the etiology is degenerative or genetically mediated. For patients with degenerative descending TAA, we suggest an endovascular approach for initial repair rather than an open approach, provided the thoracic aortic anatomy is suitable for endografting (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Endovascular repair is associated with reduced perioperative morbidity and mortality; however, the long-term durability of endovascular TAA repair compared with open surgical repair remains uncertain. An open approach should be used for those with syndromic TAAD. The approach for those with nonsyndromic TAAD is less well defined. </p><p></p><p class="headingAnchor" id="H1665046417"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Emile R Mohler, III, MD (deceased), who contributed to an earlier version of this topic review.</p><p>The UpToDate editorial staff acknowledges Y Joseph Woo, MD and Christina L Greene, MD, who contributed to an earlier version of this topic. </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Erbel R, Aboyans V, Boileau C, et al. [2014 ESC Guidelines on the diagnosis and treatment of aortic diseases]. Kardiol Pol 2014; 72:1169.</a></li><li><a class="nounderline abstract_t">Boodhwani M, Andelfinger G, Leipsic J, et al. Canadian Cardiovascular Society position statement on the management of thoracic aortic disease. Can J Cardiol 2014; 30:577.</a></li><li><a class="nounderline abstract_t">Svensson LG, Adams DH, Bonow RO, et al. Aortic valve and ascending aorta guidelines for management and quality measures. Ann Thorac Surg 2013; 95:S1.</a></li><li><a class="nounderline abstract_t">Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 2010; 121:e266.</a></li><li><a class="nounderline abstract_t">2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM GUIDELINES FOR THE DIAGNOSIS AND MANAGEMENT OF PATIENTS WITH THORACIC AORTIC DISEASE REPRESENTATIVE MEMBERS*, Hiratzka LF, Creager MA, et al. Surgery for Aortic Dilatation in Patients With Bicuspid Aortic Valves: A Statement of Clarification From the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2016; 133:680.</a></li><li><a class="nounderline abstract_t">Knipp BS, Deeb GM, Prager RL, et al. A contemporary analysis of outcomes for operative repair of type A aortic dissection in the United States. Surgery 2007; 142:524.</a></li><li><a class="nounderline abstract_t">Isselbacher EM, Preventza O, Hamilton Black J 3rd, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation 2022; 146:e334.</a></li><li><a class="nounderline abstract_t">Erbel R, Aboyans V, Boileau C, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J 2014; 35:2873.</a></li><li><a class="nounderline abstract_t">Davies RR, Gallo A, Coady MA, et al. Novel measurement of relative aortic size predicts rupture of thoracic aortic aneurysms. Ann Thorac Surg 2006; 81:169.</a></li><li><a class="nounderline abstract_t">Hiratzka LF, Creager MA, Isselbacher EM, et al. Surgery for Aortic Dilatation in Patients With Bicuspid Aortic Valves: A Statement of Clarification From the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016; 67:724.</a></li><li><a class="nounderline abstract_t">Lobato AC, Puech-Leão P. Predictive factors for rupture of thoracoabdominal aortic aneurysm. J Vasc Surg 1998; 27:446.</a></li><li><a class="nounderline abstract_t">Pape LA, Tsai TT, Isselbacher EM, et al. Aortic diameter &gt;or = 5.5 cm is not a good predictor of type A aortic dissection: observations from the International Registry of Acute Aortic Dissection (IRAD). Circulation 2007; 116:1120.</a></li><li><a class="nounderline abstract_t">Griepp RB, Ergin MA, Lansman SL, et al. The natural history of thoracic aortic aneurysms. Semin Thorac Cardiovasc Surg 1991; 3:258.</a></li><li><a class="nounderline abstract_t">Bickerstaff LK, Pairolero PC, Hollier LH, et al. Thoracic aortic aneurysms: a population-based study. Surgery 1982; 92:1103.</a></li><li><a class="nounderline abstract_t">Pressler V, McNamara JJ. Thoracic aortic aneurysm: natural history and treatment. J Thorac Cardiovasc Surg 1980; 79:489.</a></li><li><a class="nounderline abstract_t">Crawford ES, DeNatale RW. Thoracoabdominal aortic aneurysm: observations regarding the natural course of the disease. J Vasc Surg 1986; 3:578.</a></li><li><a class="nounderline abstract_t">Davies RR, Goldstein LJ, Coady MA, et al. Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg 2002; 73:17.</a></li><li><a class="nounderline abstract_t">Hansen PA, Richards JM, Tambyraja AL, et al. Natural history of thoraco-abdominal aneurysm in high-risk patients. Eur J Vasc Endovasc Surg 2010; 39:266.</a></li><li><a class="nounderline abstract_t">Johansson G, Markström U, Swedenborg J. Ruptured thoracic aortic aneurysms: a study of incidence and mortality rates. J Vasc Surg 1995; 21:985.</a></li><li><a class="nounderline abstract_t">Geisbüsch P, Kotelis D, Weber TF, et al. Endovascular repair of ruptured thoracic aortic aneurysms is associated with high perioperative mortality and morbidity. J Vasc Surg 2010; 51:299.</a></li><li><a class="nounderline abstract_t">Elefteriades JA, Farkas EA. Thoracic aortic aneurysm clinically pertinent controversies and uncertainties. J Am Coll Cardiol 2010; 55:841.</a></li><li><a class="nounderline abstract_t">Elefteriades JA. Indications for aortic replacement. J Thorac Cardiovasc Surg 2010; 140:S5.</a></li><li><a class="nounderline abstract_t">Clouse WD, Hallett JW Jr, Schaff HV, et al. Improved prognosis of thoracic aortic aneurysms: a population-based study. JAMA 1998; 280:1926.</a></li><li><a class="nounderline abstract_t">Juvonen T, Ergin MA, Galla JD, et al. Prospective study of the natural history of thoracic aortic aneurysms. Ann Thorac Surg 1997; 63:1533.</a></li><li><a class="nounderline abstract_t">Coady MA, Rizzo JA, Hammond GL, et al. Surgical intervention criteria for thoracic aortic aneurysms: a study of growth rates and complications. Ann Thorac Surg 1999; 67:1922.</a></li><li><a class="nounderline abstract_t">Kim JB, Kim K, Lindsay ME, et al. Risk of rupture or dissection in descending thoracic aortic aneurysm. Circulation 2015; 132:1620.</a></li><li><a class="nounderline abstract_t">Coady MA, Rizzo JA, Hammond GL, et al. What is the appropriate size criterion for resection of thoracic aortic aneurysms? J Thorac Cardiovasc Surg 1997; 113:476.</a></li><li><a class="nounderline abstract_t">Koullias G, Modak R, Tranquilli M, et al. Mechanical deterioration underlies malignant behavior of aneurysmal human ascending aorta. J Thorac Cardiovasc Surg 2005; 130:677.</a></li><li><a class="nounderline abstract_t">Ziganshin BA, Zafar MA, Elefteriades JA. Descending threshold for ascending aortic aneurysmectomy: Is it time for a "left-shift" in guidelines? J Thorac Cardiovasc Surg 2019; 157:37.</a></li><li><a class="nounderline abstract_t">Jondeau G, Ropers J, Regalado E, et al. International Registry of Patients Carrying TGFBR1 or TGFBR2 Mutations: Results of the MAC (Montalcino Aortic Consortium). Circ Cardiovasc Genet 2016; 9:548.</a></li><li><a class="nounderline abstract_t">Brownstein AJ, Ziganshin BA, Kuivaniemi H, et al. Genes Associated with Thoracic Aortic Aneurysm and Dissection: An Update and Clinical Implications. Aorta (Stamford) 2017; 5:11.</a></li><li><a class="nounderline abstract_t">Fletcher AJ, Syed MBJ, Aitman TJ, et al. Inherited Thoracic Aortic Disease: New Insights and Translational Targets. Circulation 2020; 141:1570.</a></li><li><a class="nounderline abstract_t">Schoenhoff FS, Kadner A, Czerny M, et al. Should aortic arch replacement be performed during initial surgery for aortic root aneurysm in patients with Marfan syndrome? Eur J Cardiothorac Surg 2013; 44:346.</a></li><li><a class="nounderline abstract_t">Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Catheter Cardiovasc Interv 2010; 76:E43.</a></li><li><a class="nounderline abstract_t">Gott VL, Pyeritz RE, Magovern GJ Jr, et al. Surgical treatment of aneurysms of the ascending aorta in the Marfan syndrome. Results of composite-graft repair in 50 patients. N Engl J Med 1986; 314:1070.</a></li><li><a class="nounderline abstract_t">Ergin MA, Spielvogel D, Apaydin A, et al. Surgical treatment of the dilated ascending aorta: when and how? Ann Thorac Surg 1999; 67:1834.</a></li><li><a class="nounderline abstract_t">Sievers HH, Stierle U, Mohamed SA, et al. Toward individualized management of the ascending aorta in bicuspid aortic valve surgery: the role of valve phenotype in 1362 patients. J Thorac Cardiovasc Surg 2014; 148:2072.</a></li><li><a class="nounderline abstract_t">Rinewalt D, McCarthy PM, Malaisrie SC, et al. Effect of aortic aneurysm replacement on outcomes after bicuspid aortic valve surgery: validation of contemporary guidelines. J Thorac Cardiovasc Surg 2014; 148:2060.</a></li><li><a class="nounderline abstract_t">Borger MA, Preston M, Ivanov J, et al. Should the ascending aorta be replaced more frequently in patients with bicuspid aortic valve disease? J Thorac Cardiovasc Surg 2004; 128:677.</a></li><li><a class="nounderline abstract_t">Matsuyama K, Usui A, Akita T, et al. Natural history of a dilated ascending aorta after aortic valve replacement. Circ J 2005; 69:392.</a></li><li><a class="nounderline abstract_t">Svensson LG, Kim KH, Lytle BW, Cosgrove DM. Relationship of aortic cross-sectional area to height ratio and the risk of aortic dissection in patients with bicuspid aortic valves. J Thorac Cardiovasc Surg 2003; 126:892.</a></li><li><a class="nounderline abstract_t">American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006; 114:e84.</a></li><li><a class="nounderline abstract_t">Friedman T, Mani A, Elefteriades JA. Bicuspid aortic valve: clinical approach and scientific review of a common clinical entity. Expert Rev Cardiovasc Ther 2008; 6:235.</a></li><li><a class="nounderline abstract_t">Wojnarski CM, Svensson LG, Roselli EE, et al. Aortic Dissection in Patients With Bicuspid Aortic Valve-Associated Aneurysms. Ann Thorac Surg 2015; 100:1666.</a></li><li><a class="nounderline abstract_t">Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med 2006; 355:788.</a></li><li><a class="nounderline abstract_t">Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57.</a></li><li><a class="nounderline abstract_t">Zafar MA, Li Y, Rizzo JA, et al. Height alone, rather than body surface area, suffices for risk estimation in ascending aortic aneurysm. J Thorac Cardiovasc Surg 2018; 155:1938.</a></li><li><a class="nounderline abstract_t">Svensson LG, Khitin L. Aortic cross-sectional area/height ratio timing of aortic surgery in asymptomatic patients with Marfan syndrome. J Thorac Cardiovasc Surg 2002; 123:360.</a></li><li><a class="nounderline abstract_t">Masri A, Kalahasti V, Svensson LG, et al. Aortic Cross-Sectional Area/Height Ratio and Outcomes in Patients With Bicuspid Aortic Valve and a Dilated Ascending Aorta. Circ Cardiovasc Imaging 2017; 10:e006249.</a></li><li><a class="nounderline abstract_t">Kuzmik GA, Sang AX, Elefteriades JA. Natural history of thoracic aortic aneurysms. J Vasc Surg 2012; 56:565.</a></li><li><a class="nounderline abstract_t">Chau KH, Elefteriades JA. Natural history of thoracic aortic aneurysms: size matters, plus moving beyond size. Prog Cardiovasc Dis 2013; 56:74.</a></li><li class="breakAll">Braverman A, Thompson R, Sanchez L. Diseases of the aorta. In: Braunwald’s heart disease, 9th ed, Bonow R, Mann D, Zipes D, Libby P (Eds), Elsevier, Philadelphia 2011. p.1309.</li><li><a class="nounderline abstract_t">Bonser RS, Pagano D, Lewis ME, et al. Clinical and patho-anatomical factors affecting expansion of thoracic aortic aneurysms. Heart 2000; 84:277.</a></li><li><a class="nounderline abstract_t">Dapunt OE, Galla JD, Sadeghi AM, et al. The natural history of thoracic aortic aneurysms. J Thorac Cardiovasc Surg 1994; 107:1323.</a></li><li><a class="nounderline abstract_t">Griepp RB, Ergin MA, Galla JD, et al. Natural history of descending thoracic and thoracoabdominal aneurysms. Ann Thorac Surg 1999; 67:1927.</a></li><li><a class="nounderline abstract_t">Sueyoshi E, Sakamoto I, Hayashi K, et al. Growth rate of aortic diameter in patients with type B aortic dissection during the chronic phase. Circulation 2004; 110:II256.</a></li><li><a class="nounderline abstract_t">Booher AM, Eagle KA. Diagnosis and management issues in thoracic aortic aneurysm. Am Heart J 2011; 162:38.</a></li><li><a class="nounderline abstract_t">Coady MA, Davies RR, Roberts M, et al. Familial patterns of thoracic aortic aneurysms. Arch Surg 1999; 134:361.</a></li><li><a class="nounderline abstract_t">Shang EK, Nathan DP, Sprinkle SR, et al. Peak wall stress predicts expansion rate in descending thoracic aortic aneurysms. Ann Thorac Surg 2013; 95:593.</a></li><li><a class="nounderline abstract_t">Shang EK, Nathan DP, Boonn WW, et al. A modern experience with saccular aortic aneurysms. J Vasc Surg 2013; 57:84.</a></li><li><a class="nounderline abstract_t">Albornoz G, Coady MA, Roberts M, et al. Familial thoracic aortic aneurysms and dissections--incidence, modes of inheritance, and phenotypic patterns. Ann Thorac Surg 2006; 82:1400.</a></li><li><a class="nounderline abstract_t">Verma S, Siu SC. Aortic dilatation in patients with bicuspid aortic valve. N Engl J Med 2014; 370:1920.</a></li><li><a class="nounderline abstract_t">Davies RR, Kaple RK, Mandapati D, et al. Natural history of ascending aortic aneurysms in the setting of an unreplaced bicuspid aortic valve. Ann Thorac Surg 2007; 83:1338.</a></li><li><a class="nounderline abstract_t">La Canna G, Ficarra E, Tsagalau E, et al. Progression rate of ascending aortic dilation in patients with normally functioning bicuspid and tricuspid aortic valves. Am J Cardiol 2006; 98:249.</a></li><li><a class="nounderline abstract_t">Meijboom LJ, Timmermans J, Zwinderman AH, et al. Aortic root growth in men and women with the Marfan's syndrome. Am J Cardiol 2005; 96:1441.</a></li><li><a class="nounderline abstract_t">Donnelly RT, Pinto NM, Kocolas I, Yetman AT. The immediate and long-term impact of pregnancy on aortic growth rate and mortality in women with Marfan syndrome. J Am Coll Cardiol 2012; 60:224.</a></li><li><a class="nounderline abstract_t">Meijboom LJ, Vos FE, Timmermans J, et al. Pregnancy and aortic root growth in the Marfan syndrome: a prospective study. Eur Heart J 2005; 26:914.</a></li><li><a class="nounderline abstract_t">Rossiter JP, Repke JT, Morales AJ, et al. A prospective longitudinal evaluation of pregnancy in the Marfan syndrome. Am J Obstet Gynecol 1995; 173:1599.</a></li><li><a class="nounderline abstract_t">Chun AS, Elefteriades JA, Mukherjee SK. Medical treatment for thoracic aortic aneurysm - much more work to be done. Prog Cardiovasc Dis 2013; 56:103.</a></li><li><a class="nounderline abstract_t">Braverman AC. Medical management of thoracic aortic aneurysm disease. J Thorac Cardiovasc Surg 2013; 145:S2.</a></li><li><a class="nounderline abstract_t">Danyi P, Elefteriades JA, Jovin IS. Medical therapy of thoracic aortic aneurysms: are we there yet? Circulation 2011; 124:1469.</a></li><li><a class="nounderline abstract_t">Jaldin RG, Castardelli É, Perobelli JE, et al. Morphologic and biomechanical changes of thoracic and abdominal aorta in a rat model of cigarette smoke exposure. Ann Vasc Surg 2013; 27:791.</a></li><li><a class="nounderline abstract_t">Lacro RV, Dietz HC, Wruck LM, et al. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J 2007; 154:624.</a></li><li><a class="nounderline abstract_t">Elefteriades JA. Does medical therapy for thoracic aortic aneurysms really work? Are beta-blockers truly indicated? PRO. Cardiol Clin 2010; 28:255.</a></li><li><a class="nounderline abstract_t">Liao SL, Elmariah S, van der Zee S, et al. Does medical therapy for thoracic aortic aneurysms really work? Are beta-blockers truly indicated? CON. Cardiol Clin 2010; 28:261.</a></li><li><a class="nounderline abstract_t">Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.</a></li><li><a class="nounderline abstract_t">Groenink M, de Roos A, Mulder BJ, et al. Changes in aortic distensibility and pulse wave velocity assessed with magnetic resonance imaging following beta-blocker therapy in the Marfan syndrome. Am J Cardiol 1998; 82:203.</a></li><li><a class="nounderline abstract_t">Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med 1994; 330:1335.</a></li><li><a class="nounderline abstract_t">Ladouceur M, Fermanian C, Lupoglazoff JM, et al. Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome. Am J Cardiol 2007; 99:406.</a></li><li><a class="nounderline abstract_t">Pyeritz RE, Loeys B. The 8th international research symposium on the Marfan syndrome and related conditions. Am J Med Genet A 2012; 158A:42.</a></li><li><a class="nounderline abstract_t">Milleron O, Arnoult F, Ropers J, et al. Marfan Sartan: a randomized, double-blind, placebo-controlled trial. Eur Heart J 2015; 36:2160.</a></li><li><a class="nounderline abstract_t">Habashi JP, Doyle JJ, Holm TM, et al. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 2011; 332:361.</a></li><li><a class="nounderline abstract_t">Moltzer E, Essers J, van Esch JH, et al. The role of the renin-angiotensin system in thoracic aortic aneurysms: clinical implications. Pharmacol Ther 2011; 131:50.</a></li><li><a class="nounderline abstract_t">Lindsay ME, Dietz HC. Lessons on the pathogenesis of aneurysm from heritable conditions. Nature 2011; 473:308.</a></li><li><a class="nounderline abstract_t">Singh MN, Lacro RV. Recent Clinical Drug Trials Evidence in Marfan Syndrome and Clinical Implications. Can J Cardiol 2016; 32:66.</a></li><li><a class="nounderline abstract_t">Groenink M, den Hartog AW, Franken R, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J 2013; 34:3491.</a></li><li><a class="nounderline abstract_t">Yetman AT, Bornemeier RA, McCrindle BW. Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Am J Cardiol 2005; 95:1125.</a></li><li><a class="nounderline abstract_t">Brooke BS, Habashi JP, Judge DP, et al. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 2008; 358:2787.</a></li><li><a class="nounderline abstract_t">Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006; 312:117.</a></li><li><a class="nounderline abstract_t">Lacro RV, Dietz HC, Sleeper LA, et al. Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med 2014; 371:2061.</a></li><li><a class="nounderline abstract_t">Forteza A, Evangelista A, Sánchez V, et al. Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial. Eur Heart J 2016; 37:978.</a></li><li><a class="nounderline abstract_t">Ferguson CD, Clancy P, Bourke B, et al. Association of statin prescription with small abdominal aortic aneurysm progression. Am Heart J 2010; 159:307.</a></li><li><a class="nounderline abstract_t">Kertai MD, Boersma E, Westerhout CM, et al. Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. Am J Med 2004; 116:96.</a></li><li><a class="nounderline abstract_t">Sukhija R, Aronow WS, Sandhu R, et al. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol 2006; 97:279.</a></li><li><a class="nounderline abstract_t">Diehm N, Becker G, Katzen B, et al. Statins are associated with decreased mortality in abdominal, but not in thoracic aortic aneurysm patients undergoing endovascular repair: propensity score-adjusted analysis. Vasa 2008; 37:241.</a></li><li><a class="nounderline abstract_t">Stein LH, Berger J, Tranquilli M, Elefteraides JA. Effect of statin drugs on thoracic aortic aneurysms. Am J Cardiol 2013; 112:1240.</a></li><li><a class="nounderline abstract_t">McLoughlin D, McGuinness J, Byrne J, et al. Pravastatin reduces Marfan aortic dilation. Circulation 2011; 124:S168.</a></li><li><a class="nounderline abstract_t">Jovin IS, Duggal M, Ebisu K, et al. Comparison of the effect on long-term outcomes in patients with thoracic aortic aneurysms of taking versus not taking a statin drug. Am J Cardiol 2012; 109:1050.</a></li><li class="breakAll">Stein LH, Berger J, Tranquilli M, Elefteriades JA. Statin therapy and the natural history of thoracic aortic aneurysm. American Association of Thoracic Surgery Aortic Symposium. April 24-25, 2014.</li><li><a class="nounderline abstract_t">Chung AW, Yang HH, Radomski MW, van Breemen C. Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9. Circ Res 2008; 102:e73.</a></li><li><a class="nounderline abstract_t">Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ 2018; 360:k678.</a></li><li class="breakAll">https://www.fda.gov/news-events/fda-brief/fda-brief-fda-warns-fluoroquinolone-antibiotics-can-cause-aortic-aneurysm-certain-patients (Accessed on January 25, 2019).</li><li><a class="nounderline abstract_t">Mani K, Wanhainen A. Accurate and reproducible diameter measurement is essential in surveillance and treatment of thoracic aortic aneurysms. Eur J Vasc Endovasc Surg 2014; 47:27.</a></li><li><a class="nounderline abstract_t">Ziganshin BA, Bailey AE, Coons C, et al. Routine Genetic Testing for Thoracic Aortic Aneurysm and Dissection in a Clinical Setting. Ann Thorac Surg 2015; 100:1604.</a></li><li><a class="nounderline abstract_t">Hoffjan S, Waldmüller S, Blankenfeldt W, et al. Three novel mutations in the ACTA2 gene in German patients with thoracic aortic aneurysms and dissections. Eur J Hum Genet 2011; 19:520.</a></li><li><a class="nounderline abstract_t">Sherrah AG, Andvik S, van der Linde D, et al. Nonsyndromic Thoracic Aortic Aneurysm and Dissection: Outcomes With Marfan Syndrome Versus Bicuspid Aortic Valve Aneurysm. J Am Coll Cardiol 2016; 67:618.</a></li><li><a class="nounderline abstract_t">Arbustini E, Narula N. Extra-aortic identifiers to guide genetic testing in familial thoracic aortic aneurysms and dissections syndromes: it is all about the company one keeps. J Am Coll Cardiol 2012; 60:404.</a></li><li><a class="nounderline abstract_t">Biner S, Rafique AM, Ray I, et al. Aortopathy is prevalent in relatives of bicuspid aortic valve patients. J Am Coll Cardiol 2009; 53:2288.</a></li><li><a class="nounderline abstract_t">Guo DC, Papke CL, He R, Milewicz DM. Pathogenesis of thoracic and abdominal aortic aneurysms. Ann N Y Acad Sci 2006; 1085:339.</a></li><li><a class="nounderline abstract_t">DeFreitas MR, Quint LE, Watcharotone K, et al. Evaluation for abdominal aortic aneurysms is justified in patients with thoracic aortic aneurysms. Int J Cardiovasc Imaging 2016; 32:647.</a></li><li><a class="nounderline abstract_t">Kuzmik GA, Feldman M, Tranquilli M, et al. Concurrent intracranial and thoracic aortic aneurysms. Am J Cardiol 2010; 105:417.</a></li><li><a class="nounderline abstract_t">Wanga S, Silversides C, Dore A, et al. Pregnancy and Thoracic Aortic Disease: Managing the Risks. Can J Cardiol 2016; 32:78.</a></li><li><a class="nounderline abstract_t">Fazel SS, David TE. Aortic valve-sparing operations for aortic root and ascending aortic aneurysms. Curr Opin Cardiol 2007; 22:497.</a></li><li><a class="nounderline abstract_t">Veldtman GR, Connolly HM, Orszulak TA, et al. Fate of bicuspid aortic valves in patients undergoing aortic root repair or replacement for aortic root enlargement. Mayo Clin Proc 2006; 81:322.</a></li><li><a class="nounderline abstract_t">Mewhort HE, Appoo JJ, Sumner GL, et al. Alternative surgical approach to repair of the ascending aorta. Ann Thorac Surg 2011; 92:1108.</a></li><li><a class="nounderline abstract_t">Rosset E, Ben Ahmed S, Galvaing G, et al. Editor's choice--hybrid treatment of thoracic, thoracoabdominal, and abdominal aortic aneurysms: a multicenter retrospective study. Eur J Vasc Endovasc Surg 2014; 47:470.</a></li><li><a class="nounderline abstract_t">Bianchini Massoni C, Geisbüsch P, Gallitto E, et al. Follow-up outcomes of hybrid procedures for thoracoabdominal aortic pathologies with special focus on graft patency and late mortality. J Vasc Surg 2014; 59:1265.</a></li><li><a class="nounderline abstract_t">Johnston WF, Upchurch GR Jr, Tracci MC, et al. Staged hybrid approach using proximal thoracic endovascular aneurysm repair and distal open repair for the treatment of extensive thoracoabdominal aortic aneurysms. J Vasc Surg 2012; 56:1495.</a></li><li><a class="nounderline abstract_t">Murashita T, Matsuda H, Domae K, et al. Less invasive surgical treatment for aortic arch aneurysms in high-risk patients: a comparative study of hybrid thoracic endovascular aortic repair and conventional total arch replacement. J Thorac Cardiovasc Surg 2012; 143:1007.</a></li><li><a class="nounderline abstract_t">Patel R, Conrad MF, Paruchuri V, et al. Thoracoabdominal aneurysm repair: hybrid versus open repair. J Vasc Surg 2009; 50:15.</a></li><li><a class="nounderline abstract_t">Quinones-Baldrich W, Jimenez JC, DeRubertis B, Moore WS. Combined endovascular and surgical approach (CESA) to thoracoabdominal aortic pathology: A 10-year experience. J Vasc Surg 2009; 49:1125.</a></li><li><a class="nounderline abstract_t">Moulakakis KG, Mylonas SN, Avgerinos ED, et al. Hybrid open endovascular technique for aortic thoracoabdominal pathologies. Circulation 2011; 124:2670.</a></li><li><a class="nounderline abstract_t">Vallejo N, Rodriguez-Lopez JA, Heidari P, et al. Hybrid repair of thoracic aortic lesions for zone 0 and 1 in high-risk patients. J Vasc Surg 2012; 55:318.</a></li><li><a class="nounderline abstract_t">Preventza O, Mohammed S, Cheong BY, et al. Endovascular therapy in patients with genetically triggered thoracic aortic disease: applications and short- and mid-term outcomes. Eur J Cardiothorac Surg 2014; 46:248.</a></li><li><a class="nounderline abstract_t">Walsh SR, Tang TY, Sadat U, et al. Endovascular stenting versus open surgery for thoracic aortic disease: systematic review and meta-analysis of perioperative results. J Vasc Surg 2008; 47:1094.</a></li><li><a class="nounderline abstract_t">Cheng D, Martin J, Shennib H, et al. Endovascular aortic repair versus open surgical repair for descending thoracic aortic disease a systematic review and meta-analysis of comparative studies. J Am Coll Cardiol 2010; 55:986.</a></li><li><a class="nounderline abstract_t">Abraha I, Romagnoli C, Montedori A, Cirocchi R. Thoracic stent graft versus surgery for thoracic aneurysm. Cochrane Database Syst Rev 2013; :CD006796.</a></li><li><a class="nounderline abstract_t">Gøtzsche CO, Krag-Olsen B, Nielsen J, et al. Prevalence of cardiovascular malformations and association with karyotypes in Turner's syndrome. Arch Dis Child 1994; 71:433.</a></li><li><a class="nounderline abstract_t">Matsumura JS, Cambria RP, Dake MD, et al. International controlled clinical trial of thoracic endovascular aneurysm repair with the Zenith TX2 endovascular graft: 1-year results. J Vasc Surg 2008; 47:247.</a></li><li><a class="nounderline abstract_t">Bavaria JE, Appoo JJ, Makaroun MS, et al. Endovascular stent grafting versus open surgical repair of descending thoracic aortic aneurysms in low-risk patients: a multicenter comparative trial. J Thorac Cardiovasc Surg 2007; 133:369.</a></li><li><a class="nounderline abstract_t">Makaroun MS, Dillavou ED, Wheatley GH, et al. Five-year results of endovascular treatment with the Gore TAG device compared with open repair of thoracic aortic aneurysms. J Vasc Surg 2008; 47:912.</a></li><li><a class="nounderline abstract_t">Svensson LG, Kouchoukos NT, Miller DC, et al. Expert consensus document on the treatment of descending thoracic aortic disease using endovascular stent-grafts. Ann Thorac Surg 2008; 85:S1.</a></li><li><a class="nounderline abstract_t">Svensson LG, Crawford ES, Hess KR, et al. Experience with 1509 patients undergoing thoracoabdominal aortic operations. J Vasc Surg 1993; 17:357.</a></li><li><a class="nounderline abstract_t">Greenberg RK, Lu Q, Roselli EE, et al. Contemporary analysis of descending thoracic and thoracoabdominal aneurysm repair: a comparison of endovascular and open techniques. Circulation 2008; 118:808.</a></li><li><a class="nounderline abstract_t">Jackson BM, Carpenter JP, Fairman RM, et al. Anatomic exclusion from endovascular repair of thoracic aortic aneurysm. J Vasc Surg 2007; 45:662.</a></li><li><a class="nounderline abstract_t">Leurs LJ, Bell R, Degrieck Y, et al. Endovascular treatment of thoracic aortic diseases: combined experience from the EUROSTAR and United Kingdom Thoracic Endograft registries. J Vasc Surg 2004; 40:670.</a></li><li><a class="nounderline abstract_t">Boeckxstaens CJ, Flameng WJ. Retrograde cerebral perfusion does not perfuse the brain in nonhuman primates. Ann Thorac Surg 1995; 60:319.</a></li><li><a class="nounderline abstract_t">Gopaldas RR, Dao TK, LeMaire SA, et al. Endovascular versus open repair of ruptured descending thoracic aortic aneurysms: a nationwide risk-adjusted study of 923 patients. J Thorac Cardiovasc Surg 2011; 142:1010.</a></li><li><a class="nounderline abstract_t">Kilic A, Shah AS, Black JH 3rd, et al. Trends in repair of intact and ruptured descending thoracic aortic aneurysms in the United States: a population-based analysis. J Thorac Cardiovasc Surg 2014; 147:1855.</a></li><li><a class="nounderline abstract_t">Doss M, Wood JP, Balzer J, et al. Emergency endovascular interventions for acute thoracic aortic rupture: four-year follow-up. J Thorac Cardiovasc Surg 2005; 129:645.</a></li></ol></div><div id="topicVersionRevision">Topic 8189 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25524604" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : [2014 ESC Guidelines on the diagnosis and treatment of aortic diseases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24882528" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Canadian Cardiovascular Society position statement on the management of thoracic aortic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23688839" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Aortic valve and ascending aorta guidelines for management and quality measures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20233780" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26637530" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Surgery for Aortic Dilatation in Patients With Bicuspid Aortic Valves: A Statement of Clarification From the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17950344" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A contemporary analysis of outcomes for operative repair of type A aortic dissection in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36322642" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25173340" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16368358" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Novel measurement of relative aortic size predicts rupture of thoracic aortic aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26658475" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Surgery for Aortic Dilatation in Patients With Bicuspid Aortic Valves: A Statement of Clarification From the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9580243" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Predictive factors for rupture of thoracoabdominal aortic aneurysm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17709637" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Aortic diameter&gt;or = 5.5 cm is not a good predictor of type A aortic dissection: observations from the International Registry of Acute Aortic Dissection (IRAD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1793761" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The natural history of thoracic aortic aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7147188" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Thoracic aortic aneurysms: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7359927" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Thoracic aortic aneurysm: natural history and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3959256" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Thoracoabdominal aortic aneurysm: observations regarding the natural course of the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11834007" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20071200" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Natural history of thoraco-abdominal aneurysm in high-risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7776479" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Ruptured thoracic aortic aneurysms: a study of incidence and mortality rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20141954" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Endovascular repair of ruptured thoracic aortic aneurysms is associated with high perioperative mortality and morbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20185035" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Thoracic aortic aneurysm clinically pertinent controversies and uncertainties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21092797" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Indications for aortic replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9851478" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Improved prognosis of thoracic aortic aneurysms: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9205145" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prospective study of the natural history of thoracic aortic aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10391339" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Surgical intervention criteria for thoracic aortic aneurysms: a study of growth rates and complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26338955" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Risk of rupture or dissection in descending thoracic aortic aneurysm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9081092" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : What is the appropriate size criterion for resection of thoracic aortic aneurysms?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16153912" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Mechanical deterioration underlies malignant behavior of aneurysmal human ascending aorta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30557953" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Descending threshold for ascending aortic aneurysmectomy: Is it time for a "left-shift" in guidelines?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27879313" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : International Registry of Patients Carrying TGFBR1 or TGFBR2 Mutations: Results of the MAC (Montalcino Aortic Consortium).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28868310" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Genes Associated with Thoracic Aortic Aneurysm and Dissection: An Update and Clinical Implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32392100" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Inherited Thoracic Aortic Disease: New Insights and Translational Targets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23359416" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Should aortic arch replacement be performed during initial surgery for aortic root aneurysm in patients with Marfan syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20687249" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2938007" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Surgical treatment of aneurysms of the ascending aorta in the Marfan syndrome. Results of composite-graft repair in 50 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10391320" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Surgical treatment of the dilated ascending aorta: when and how?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24841446" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Toward individualized management of the ascending aorta in bicuspid aortic valve surgery: the role of valve phenotype in 1362 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24755330" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effect of aortic aneurysm replacement on outcomes after bicuspid aortic valve surgery: validation of contemporary guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15514594" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Should the ascending aorta be replaced more frequently in patients with bicuspid aortic valve disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15791031" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Natural history of a dilated ascending aorta after aortic valve replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14502185" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Relationship of aortic cross-sectional area to height ratio and the risk of aortic dissection in patients with bicuspid aortic valves.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16880336" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18248277" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Bicuspid aortic valve: clinical approach and scientific review of a common clinical entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26209494" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Aortic Dissection in Patients With Bicuspid Aortic Valve-Associated Aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16928994" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Aneurysm syndromes caused by mutations in the TGF-beta receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24603191" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29395211" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Height alone, rather than body surface area, suffices for risk estimation in ascending aortic aneurysm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11828302" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Aortic cross-sectional area/height ratio timing of aortic surgery in asymptomatic patients with Marfan syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28592593" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Aortic Cross-Sectional Area/Height Ratio and Outcomes in Patients With Bicuspid Aortic Valve and a Dilated Ascending Aorta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22840907" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Natural history of thoracic aortic aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23993240" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Natural history of thoracic aortic aneurysms: size matters, plus moving beyond size.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23993240" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Natural history of thoracic aortic aneurysms: size matters, plus moving beyond size.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10956290" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical and patho-anatomical factors affecting expansion of thoracic aortic aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8176976" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The natural history of thoracic aortic aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10391340" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Natural history of descending thoracic and thoracoabdominal aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15364872" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Growth rate of aortic diameter in patients with type B aortic dissection during the chronic phase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21742088" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Diagnosis and management issues in thoracic aortic aneurysm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10199307" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Familial patterns of thoracic aortic aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23245445" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Peak wall stress predicts expansion rate in descending thoracic aortic aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23127980" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A modern experience with saccular aortic aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16996941" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Familial thoracic aortic aneurysms and dissections--incidence, modes of inheritance, and phenotypic patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24827036" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Aortic dilatation in patients with bicuspid aortic valve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17383337" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Natural history of ascending aortic aneurysms in the setting of an unreplaced bicuspid aortic valve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16828602" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Progression rate of ascending aortic dilation in patients with normally functioning bicuspid and tricuspid aortic valves.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16275195" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Aortic root growth in men and women with the Marfan's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22789886" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The immediate and long-term impact of pregnancy on aortic growth rate and mortality in women with Marfan syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15681576" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Pregnancy and aortic root growth in the Marfan syndrome: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7503207" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A prospective longitudinal evaluation of pregnancy in the Marfan syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23993243" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Medical treatment for thoracic aortic aneurysm - much more work to be done.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23260459" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Medical management of thoracic aortic aneurysm disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21947934" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Medical therapy of thoracic aortic aneurysms: are we there yet?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23880458" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Morphologic and biomechanical changes of thoracic and abdominal aorta in a rat model of cigarette smoke exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17892982" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20452538" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Does medical therapy for thoracic aortic aneurysms really work? Are beta-blockers truly indicated? PRO.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20452539" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Does medical therapy for thoracic aortic aneurysms really work? Are beta-blockers truly indicated? CON.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18820172" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9678292" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Changes in aortic distensibility and pulse wave velocity assessed with magnetic resonance imaging following beta-blocker therapy in the Marfan syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8152445" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17261408" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22140025" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The 8th international research symposium on the Marfan syndrome and related conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25935877" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Marfan Sartan: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21493863" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21504760" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The role of the renin-angiotensin system in thoracic aortic aneurysms: clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21593863" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Lessons on the pathogenesis of aneurysm from heritable conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26724512" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Recent Clinical Drug Trials Evidence in Marfan Syndrome and Clinical Implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23999449" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15842990" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18579813" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Angiotensin II blockade and aortic-root dilation in Marfan's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16601194" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25405392" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Atenolol versus losartan in children and young adults with Marfan's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26518245" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20152231" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Association of statin prescription with small abdominal aortic aneurysm progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14715323" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16442379" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18690591" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Statins are associated with decreased mortality in abdominal, but not in thoracic aortic aneurysm patients undergoing endovascular repair: propensity score-adjusted analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24079445" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Effect of statin drugs on thoracic aortic aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21911808" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Pravastatin reduces Marfan aortic dilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22221941" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Comparison of the effect on long-term outcomes in patients with thoracic aortic aneurysms of taking versus not taking a statin drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22221941" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Comparison of the effect on long-term outcomes in patients with thoracic aortic aneurysms of taking versus not taking a statin drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18388324" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29519881" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29519881" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24183251" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Accurate and reproducible diameter measurement is essential in surveillance and treatment of thoracic aortic aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26188975" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Routine Genetic Testing for Thoracic Aortic Aneurysm and Dissection in a Clinical Setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21248741" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Three novel mutations in the ACTA2 gene in German patients with thoracic aortic aneurysms and dissections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26868685" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Nonsyndromic Thoracic Aortic Aneurysm and Dissection: Outcomes With Marfan Syndrome Versus Bicuspid Aortic Valve Aneurysm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22633652" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Extra-aortic identifiers to guide genetic testing in familial thoracic aortic aneurysms and dissections syndromes: it is all about the company one keeps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19520254" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Aortopathy is prevalent in relatives of bicuspid aortic valve patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17182954" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Pathogenesis of thoracic and abdominal aortic aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26602411" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Evaluation for abdominal aortic aneurysms is justified in patients with thoracic aortic aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20102960" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Concurrent intracranial and thoracic aortic aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26604124" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Pregnancy and Thoracic Aortic Disease: Managing the Risks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17921735" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Aortic valve-sparing operations for aortic root and ascending aortic aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16529135" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Fate of bicuspid aortic valves in patients undergoing aortic root repair or replacement for aortic root enlargement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21871310" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Alternative surgical approach to repair of the ascending aorta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24656593" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Editor's choice--hybrid treatment of thoracic, thoracoabdominal, and abdominal aortic aneurysms: a multicenter retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24468283" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Follow-up outcomes of hybrid procedures for thoracoabdominal aortic pathologies with special focus on graft patency and late mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22832268" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Staged hybrid approach using proximal thoracic endovascular aneurysm repair and distal open repair for the treatment of extensive thoracoabdominal aortic aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21783209" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Less invasive surgical treatment for aortic arch aneurysms in high-risk patients: a comparative study of hybrid thoracic endovascular aortic repair and conventional total arch replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19563950" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Thoracoabdominal aneurysm repair: hybrid versus open repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19394542" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Combined endovascular and surgical approach (CESA) to thoracoabdominal aortic pathology: A 10-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22086877" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Hybrid open endovascular technique for aortic thoracoabdominal pathologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22047829" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Hybrid repair of thoracic aortic lesions for zone 0 and 1 in high-risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24477738" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Endovascular therapy in patients with genetically triggered thoracic aortic disease: applications and short- and mid-term outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18242941" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Endovascular stenting versus open surgery for thoracic aortic disease: systematic review and meta-analysis of perioperative results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20137879" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Endovascular aortic repair versus open surgical repair for descending thoracic aortic disease a systematic review and meta-analysis of comparative studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24027129" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Thoracic stent graft versus surgery for thoracic aneurysm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7826114" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Prevalence of cardiovascular malformations and association with karyotypes in Turner's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18241743" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : International controlled clinical trial of thoracic endovascular aneurysm repair with the Zenith TX2 endovascular graft: 1-year results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17258566" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Endovascular stent grafting versus open surgical repair of descending thoracic aortic aneurysms in low-risk patients: a multicenter comparative trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18353605" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Five-year results of endovascular treatment with the Gore TAG device compared with open repair of thoracic aortic aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18083364" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Expert consensus document on the treatment of descending thoracic aortic disease using endovascular stent-grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8433431" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Experience with 1509 patients undergoing thoracoabdominal aortic operations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18678769" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Contemporary analysis of descending thoracic and thoracoabdominal aneurysm repair: a comparison of endovascular and open techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17350215" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Anatomic exclusion from endovascular repair of thoracic aortic aneurysm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15472593" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Endovascular treatment of thoracic aortic diseases: combined experience from the EUROSTAR and United Kingdom Thoracic Endograft registries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7646092" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Retrograde cerebral perfusion does not perfuse the brain in nonhuman primates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21907356" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Endovascular versus open repair of ruptured descending thoracic aortic aneurysms: a nationwide risk-adjusted study of 923 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23993033" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Trends in repair of intact and ruptured descending thoracic aortic aneurysms in the United States: a population-based analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15746750" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Emergency endovascular interventions for acute thoracic aortic rupture: four-year follow-up.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
